

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

=> fil reg; d stat que 14; fil capl; d que nos 15; fil uspatf; d que nos 16
~~FILE~~ ~~REGISTRY~~ ENTERED AT 13:58:00 ON 04 JAN 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 2 JAN 2002 HIGHEST RN 380300-95-8
 DICTIONARY FILE UPDATES: 2 JAN 2002 HIGHEST RN 380300-95-8

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
 for more information. See STNote 27, Searching Properties in the CAS
 Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1

STR



CH2-G2-O CH2-G2-N
 @24 25 @26 @27 28 @29

VAR G1=22-9 23-20/22-20 23-9/24-9 26-20/27-9 29-20/27-20 29-9

REP G2=(0-1) CH2

NODE ATTRIBUTES:

NSPEC IS RC AT 20

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

~~L4~~ 401 SEA FILE=REGISTRY SSS EUL L1

100.0% PROCESSED 31845 ITERATIONS
 SEARCH TIME: 00.00.04

401 ANSWERS

FILE 'CAPLUS' ENTERED AT 13:58:01 ON 04 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 4 Jan 2002 VOL 136 ISS 1
FILE LAST UPDATED: 2 Jan 2002 (20020102/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

L1 STR
L4 401 SEA FILE=REGISTRY SSS FUL L1
L5 32 SEA FILE=CAPLUS ABB=ON L4

FILE 'USPATFULL' ENTERED AT 13:58:01 ON 04 JAN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 3 Jan 2002 (20020103/PD)
FILE LAST UPDATED: 3 Jan 2002 (20020103/ED)
HIGHEST GRANTED PATENT NUMBER: US6330719
HIGHEST APPLICATION PUBLICATION NUMBER: US2002002729
CA INDEXING IS CURRENT THROUGH 3 Jan 2002 (20020103/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 3 Jan 2002 (20020103/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2001
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2001

>>> Page images are available for patents from 1/1/1998. Patents <<<
>>> and applications are typically loaded on the day of publication.<<<
>>> Page images are available for display by the following day. <<<

>>> Image data for the /FA field are available the following update.<<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR
L4 401 SEA FILE=REGISTRY SSS FUL L1
~~L6~~ 24 SEA FILE=USPATFULL ABB=ON L4

=> dup.rem-15,16

FILE 'CAPLUS' ENTERED AT 13:58:07 ON 04 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:58:07 ON 04 JAN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L5
PROCESSING COMPLETED FOR L6


L8 52 DUP REM L5 L6 (4 DUPLICATES REMOVED)
ANSWERS '1-32' FROM FILE CAPLUS
ANSWERS '33-52' FROM FILE USPATFULL

=> d ibib abs hitstr l8 1-52; fil cao; d que nos 17; fil hom

L8 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 2001:278024 CAPLUS
DOCUMENT NUMBER: 134:311111
TITLE: Preparation of substituted biphenyls as glucagon
receptor antagonists
INVENTOR(S): Schoen, William R.; Ladouceur, Gaetan H.; Cook, James
H., II; Lease, Timothy G.; Wolanin, Donald J.; Kramss,
Richard H.; Hertzog, Donald L.; Osterhout, Martin H.
PATENT ASSIGNEE(S): Bayer Corporation, USA; Bayer A.-G.
SOURCE: U.S., 156 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6218431	B1	20010417	US 1997-904119	19970731

OTHER SOURCE(S): MARPAT 134:311111
GI



AB Substituted biphenyls I [R1a, R1b = alkyl; R2 = alkyl with substituents from 1 to 3 of SR7; R7 = Ph, or substituted Ph wherein the substituents are independently 1-5 of halogen, trifluoromethyl, alkyl, alkoxy, nitro, cyano, hydroxyl; R3 = alkyl with substituents of 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, alkyl, OR4 with R4 = H, alkyl; y = 0-3], glucagon receptor antagonists. E.g., redn. of 2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)-3-(3-trifluoromethylbenzyloxymethyl)pyridine-5-carboxylic acid Et ester with LiAlH₄ gave 76.5% 2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)-5-hydroxymethyl-3-(3-trifluoromethylbenzyloxymethyl)pyridine.


IT

124863-89-4P	202850-49-5P	202850-67-7P
202850-68-8P	202850-78-0P	202850-80-4P
202850-90-6P	202851-01-2P	202851-03-4P
202851-12-5P	202851-14-7P	202851-17-0P
202851-18-1P	202851-20-5P	202851-21-6P
202851-27-2P	202851-28-3P	202851-29-4P
202851-30-7P	202851-31-8P	202851-32-9P
202851-33-0P	202851-34-1P	202851-35-2P
202851-36-3P	202851-37-4P	202851-38-5P
202851-39-6P	202851-41-0P	202851-42-1P
202851-44-3P	202851-45-4P	202851-46-5P
202851-47-6P	202851-48-7P	202851-49-8P
202851-50-1P	202851-51-2P	202851-52-3P
202851-53-4P	202851-54-5P	202851-55-6P
202851-56-7P	202851-57-8P	202851-58-9P
202851-59-0P	202851-60-3P	202851-61-4P
202851-62-5P	202851-63-6P	202851-64-7P
202851-65-8P	202851-66-9P	202851-67-0P
202851-68-1P	202851-69-2P	202851-70-5P
202851-71-6P	202851-73-8P	202851-74-9P
202851-75-0P	202851-76-1P	202851-77-2P
202851-78-3P	202851-79-4P	202851-80-7P
202851-81-8P	202851-82-9P	202851-83-0P
202851-84-1P	202851-85-2P	202851-86-3P
202851-87-4P	202851-88-5P	202851-89-6P
202851-90-9P	202851-91-0P	202851-92-1P
202851-94-3P	202851-95-4P	202851-96-5P
202851-97-6P	202851-98-7P	202851-99-8P
202852-00-4P	202852-01-5P	202852-02-6P
202852-03-7P	202852-04-8P	202852-05-9P
202852-06-0P	202852-07-1P	202852-08-2P
202852-09-3P	202852-10-6P	202852-11-7P
202852-12-8P	202852-13-9P	202852-14-0P
202852-15-1P	202852-16-2P	202852-17-3P
202852-18-4P	202852-19-5P	202852-21-9P
202852-22-0P	202852-23-1P	202852-24-2P
202852-25-3P	202852-26-4P	202852-27-5P
202852-28-6P	202852-29-7P	202852-30-0P
202852-31-1P	202852-32-2P	202852-33-3P
202852-34-4P	202852-35-5P	202852-36-6P


202852-37-7P 202852-38-8P 202852-40-2P
 202852-41-3P 202852-42-4P 202852-43-5P
 202852-44-6P 202852-45-7P 202852-46-8P
 202852-47-9P 202852-48-0P 202852-49-1P
 202852-50-4P 202852-51-5P 202852-52-6P
 202852-53-7P 202852-54-8P 202852-55-9P
 202852-56-0P 202852-58-2P 202852-59-3P
 202852-60-6P 202852-61-7P 202852-62-8P
 202852-64-0P 202852-65-1P 202852-66-2P
 202852-67-3P 202852-68-4P 202852-69-5P
 202852-70-8P 202852-71-9P 202852-72-0P
 202852-73-1P 202852-74-2P 202852-75-3P
 202852-76-4P 202852-77-5P 202852-78-6P
 202852-79-7P 202852-80-0P 202852-81-1P
 202852-82-2P 202852-83-3P 202852-84-4P
 202852-85-5P 202852-86-6P 202852-87-7P
 202852-88-8P 202852-89-9P 202852-90-2P
 202852-91-3P 202852-92-4P 202852-93-5P
 202852-94-6P 202852-95-7P 202852-96-8P
 202852-97-9P 202852-98-0P 202852-99-1P
 202853-00-7P 202853-01-8P 202853-02-9P
 202853-03-0P 202853-04-1P 202853-05-2P
 202853-06-3P 202853-07-4P 202853-08-5P
 202853-09-6P 202853-10-9P 202853-11-0P
 202853-12-1P 202853-13-2P 202853-14-3P
 202853-16-5P 202853-17-6P 202853-18-7P
 202853-19-8P 202853-20-1P 202853-21-2P
 202853-22-3P 202853-23-4P 202853-24-5P
 202857-35-0P 202862-11-1P 334931-56-5P
 334931-63-4P 334931-64-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted biphenyls as glucagon receptor antagonists)


RN 124863-89-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202850-49-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2-ethyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202850-67-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methyl]amino]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202850-68-8 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 202850-78-0 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[1-[4-(trifluoromethyl)phenyl]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202850-80-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[1-[3-(trifluoromethyl)phenyl]ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202850-90-6 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(1-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-01-2 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[1-[4-(trifluoromethyl)phenyl]ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-03-4 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[1-[3-(trifluoromethyl)phenyl]ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-12-5 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[(2-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-14-7 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[(1-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-17-0 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-18-1 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-20-5 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202851-21-6 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202851-27-2 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]-2-[3-(trifluoromethyl)phenyl]-

(9CI) (CA INDEX NAME)




RN 202851-28-3 CAPLUS

CN 3-Pyridinemethanol, 2,4,6-tris(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-29-4 CAPLUS

CN Benzonitrile, 2-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-30-7 CAPLUS


CN Benzonitrile, 3-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-31-8 CAPLUS
 CN Benzonitrile, 4-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-32-9 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclopropyl-4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202851-33-0 CAPLUS
 CN 3-Pyridinemethanol, 2-ethyl-4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-34-1 CAPLUS
 CN 3-Pyridinemethanol, 2-ethyl-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-35-2 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy)methyl]-


2-(1-methylethyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 202851-36-3 CAPLUS
CN 3-Pyridinemethanol, 6-cyclohexyl-4-(4-fluorophenyl)-2-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202851-37-4 CAPLUS
CN 3-Pyridinemethanol, 6-cyclohexyl-4-(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-38-5 CAPLUS
CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]-2-(1-methylethyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202851-39-6 CAPLUS

CN 3-Pyridinemethanol, 6-(4-chlorophenyl)-4-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-41-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-[2-(4-fluorophenyl)ethyl]-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-42-1 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(trifluoromethyl)-5-[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-44-3 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 202851-45-4 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2-(2,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-46-5 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2-(2,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[4-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-47-6 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-48-7 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[3-(4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-49-8 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[2-(4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-50-1 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-(2-benzothiazolyl)phenyl]methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-51-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-52-3 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(2-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-53-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[4-(4-methylphenyl)sulfonyl]phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-54-5 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-(4-chlorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-55-6 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(methoxyphenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-56-7 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[3-methoxyphenyl)methoxy)methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-57-8 CAPLUS

CN 3-Pyridinemethanol, 5-[[[3,4-difluorophenyl)methoxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-58-9 CAPLUS

CN 3-Pyridinemethanol, 5-[[[2,4-difluorophenyl)methoxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-59-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[2-methylphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-60-3 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[3-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-61-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[4-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-62-5 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[1-(4-fluorophenyl)ethoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-63-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-64-7 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[4-(1-methylethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-65-8 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[2,4,6-tris(1-methylethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-66-9 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[3-methyl-5-phenoxyphenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-67-0 CAPLUS

CN 3-Pyridinemethanol, 5-[[(2,4-dichlorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-68-1 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-69-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202851-70-5 CAPLUS


CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202851-71-6 CAPLUS


CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-

6-methyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-73-8 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopropyl-4-(4-fluorophenyl)-2-methyl-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-74-9 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-75-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-76-1 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[3-(3-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-77-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[2-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-78-3 CAPLUS

CN 3-Pyridinemethanol, 5-[[4-(2-benzothiazolyl)phenyl]methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-79-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[2-(naphthalenyl)methoxy]methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-80-7 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-phenyl-5-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-81-8 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-[(4-methylphenyl)sulfonyl]phenyl]methoxy]methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-82-9 CAPLUS

CN 3-Pyridinemethanol, 4,6-bis(4-fluorophenyl)-5-[[[4-(4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-83-0 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-84-1 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-chlorophenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-85-2 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-(1-methylethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202851-86-3 CAPLUS


CN 3-Pyridinemethanol, 5-[[[3-(2-fluorophenoxy)phenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202851-87-4 CAPLUS


CN 3-Pyridinemethanol, 5-[[[3-(4-fluorophenoxy)phenyl)methoxy)methyl]-2,4-

bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-88-5 CAPLUS

3-Pyridinethanol, 5-[[(3,4-difluorophenyl)methoxy]methyl]-2,4-bis (4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-89-6 CAPLUS

3-Pyridinemethanol, 5-[[[(2,4-difluorophenyl)methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202851-90-9 CAPLUS


3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[2-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202851-91-0 CAPLUS


CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[(3-

methylphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-92-1 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[4-(4-methylphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-94-3 CAPLUS

CN 3-Pyridinemethanol, 5-[[2,4-dichlorophenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-95-4 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-96-5 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-97-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[2-chloro-4-(trifluoromethyl)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-98-7 CAPLUS

CN 3-Pyridinemethanol, 5-[[[3-([1,1'-biphenyl]-4-yloxy)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-99-8 CAPLUS


CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[[2-fluorophenyl]methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-00-4 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[3-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202852-01-5 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-methyl-5-phenoxyphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-02-6 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[4-phenoxythiophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-03-7 CAPLUS

CN 3-Pyridinemethanol, 5-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-04-8 CAPLUS


CN 3-Pyridinemethanol, 2-(2-fluorophenyl)-4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-05-9 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 202852-06-0 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-07-1 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-08-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-09-3 CAPLUS


CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-(3-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-10-6 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-11-7 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-5-[[[(3,4-difluorophenyl)methoxy)methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-12-8 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-5-[[[(4-chlorophenyl)methoxy)methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-13-9 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[2-(4-chlorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-14-0 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[4-methylphenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-15-1 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-16-2 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-5-[[2,4-dichlorophenyl]methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI)

(CA INDEX NAME)




RN 202852-17-3 CAPLUS

CN 3-Pyridinemethanol, 6-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-4-[4-fluoro-2-(phenylmethoxy)phenyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 202852-18-4 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-4-[4-fluoro-2-(phenylmethoxy)phenyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-19-5 CAPLUS

CN 3-Pyridinemethanol, 4-[4-fluoro-2-[(2-fluorophenyl)methoxy]phenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-21-9 CAPLUS



CN 3-Pyridinemethanol, 4-[4-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-22-0 CAPLUS
 CN 3-Pyridinemethanol, 4-[2-[(4-chlorophenyl)methoxy]-4-fluorophenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-23-1 CAPLUS
 CN 3-Pyridinemethanol, 4-[4-fluoro-3-[(2-fluorophenyl)methoxy]phenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-24-2 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 202852-25-3 CAPLUS
 CN 3-Pyridinemethanol, 5-[[(3,4-difluorophenyl)methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 202852-26-4 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-methyl-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN	202852-27-5	CAPLUS
CN	3-Pyridinemethanol, 2-(3-chlorophenyl)-5-[[(3,4-difluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)	




RN	202852-28-6	CAPLUS
CN	3-Pyridinemethanol, 2-(3-chlorophenyl)-4-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)	



RN 202852-29-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-[2-(4-fluorophenyl)ethyl]-5-[[4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-30-0 CAPLUS
 CN 3-Pyridinemethanol, 5-[[4-(3,4-difluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-6-[2-(4-fluorophenyl)ethyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-31-1 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-2-[(4-fluorophenyl)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-32-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-[(4-fluorophenyl)methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-33-3 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-4-(4-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-34-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-chlorophenyl)-2-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-35-5 CAPLUS

CN 3-Pyridinemethanol, 4-(4-chlorophenyl)-2-(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-36-6 CAPLUS

CN 3-Pyridinemethanol, 4-(3-chlorophenyl)-2-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-37-7 CAPLUS


CN 3-Pyridinemethanol, 4-(3-chlorophenyl)-2-(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-38-8 CAPLUS
 CN 3-Pyridinemethanol, 6-(1-ethylpropyl)-2,4-bis(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-40-2 CAPLUS
 CN 3-Pyridinemethanol, 6-(1-ethylpropyl)-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-41-3 CAPLUS
 CN 3-Pyridinemethanol, 4-(3,4-dichlorophenyl)-2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-42-4 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(3,4-dichlorophenyl)methoxy]methyl]-6-(1-methylethyl)-4-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-43-5 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-6-(1-methylethyl)-4-(3-methylphenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-44-6 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-45-7 CAPLUS

CN 3-Pyridinemethanol, 4-(3,5-dichlorophenyl)-2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-46-8 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(3-methoxyphenyl)methoxy]methyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-47-9 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-4-(2-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-48-0 CAPLUS


CN 3-Pyridinemethanol, 4-(2,3-dichlorophenyl)-2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202852-49-1 CAPLUS
 CN 3-Pyridinemethanol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI)
 (CA INDEX NAME)




RN 202852-50-4 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-4-[4-fluoro-3-(trifluoromethyl)phenyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-51-5 CAPLUS

CN 3-Pyridinemethanol, 4-[3-chloro-4-(trifluoromethyl)phenyl]-2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI)
(CA INDEX NAME)




RN 202852-52-6 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-53-7 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-6-cyclopentyl-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-54-8 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-55-9 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-5-[[[2,4-dichlorophenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-56-0 CAPLUS
CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]methyl]-6-cyclopentyl-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-58-2 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopropyl-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-59-3 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopropyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-60-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopropyl-5-[[(2,4-dichlorophenyl)methoxy]methyl]-
 2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-61-7 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-
 6-(1-methylethyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202852-62-8 CAPLUS

CN 3-Pyridinemethanol, 2,4,6-tris(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-64-0 CAPLUS

CN 3-Pyridinemethanol, 4-(2-chlorophenyl)-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-65-1 CAPLUS


CN 3-Pyridinemethanol, 4-(2-chlorophenyl)-2,6-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-66-2 CAPLUS
 CN 3-Pyridinemethanol, 4-(2,4-dichlorophenyl)-2-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-67-3 CAPLUS
 CN 3-Pyridinemethanol, 4-(2,4-dichlorophenyl)-2,6-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-68-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-[3-(trifluoromethyl)phenyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-69-5 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 202852-70-8 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-71-9 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-(3-methylphenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-72-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-6-(1-methylethyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-73-1 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-(4-methylphenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-74-2 CAPLUS


CN 3-Pyridinemethanol, 2-(2-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-75-3 CAPLUS
 CN 3-Pyridinemethanol, 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-[[4-(trifluoromethyl)phenyl]methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-76-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-(4-methoxyphenyl)-6-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-77-5 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-
 2-(4-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-78-6 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-(2-methoxyphenyl)-6-(1-
 methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA
 INDEX NAME)




RN 202852-79-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-
 2-(2-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-80-0 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-(3-methoxyphenyl)-6-(1-
 methylethyl)-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA
 INDEX NAME)




RN 202852-81-1 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(4-fluorophenyl)methoxy]methyl]-2-(3-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-82-2 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4,6-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-83-3 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4,6-bis(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-84-4 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclohexyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-85-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclohexyl-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-86-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]methyl]-6-cyclohexyl-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-87-7 CAPLUS

CN 3-Pyridinemethanol, 6-cyclohexyl-5-[[[(2,4-dichlorophenyl)methoxy]methyl]-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-88-8 CAPLUS


CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-6-cyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-89-9 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[3-(trifluoromethyl)phenyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-90-2 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 202852-91-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclobutyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-92-4 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclobutyl-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-93-5 CAPLUS

CN 3-Pyridinemethanol, 2-cycloheptyl-4,6-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-94-6 CAPLUS

CN 3-Pyridinemethanol, 2-cycloheptyl-4,6-bis(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-95-7 CAPLUS


CN 3-Pyridinemethanol, 6-cycloheptyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-96-8 CAPLUS
 CN 3-Pyridinemethanol, 6-cycloheptyl-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202852-97-9 CAPLUS
 CN 3-Pyridinemethanol, 4,6-bis(4-fluorophenyl)-2-(2-furanyl)-5-[[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-98-0 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(2-furanyl)-5-[[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-99-1 CAPLUS

CN 3-Pyridinemethanol, 6-(cyclopentylmethyl)-2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202853-00-7 CAPLUS

CN 3-Pyridinemethanol, 6-(cyclopentylmethyl)-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202853-01-8 CAPLUS

CN 3-Pyridinemethanol, 5-[[[3,5-bis(trifluoromethyl)phenyl)methoxy)methyl]-6-(cyclopentylmethyl)-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202853-02-9 CAPLUS

CN 3-Pyridinemethanol, 6-(cyclohexylmethyl)-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-03-0 CAPLUS

CN 3-Pyridinemethanol, 6-(cyclohexylmethyl)-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-04-1 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[4-(trifluoromethyl)phenyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-05-2 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[4-(trifluoromethyl)phenyl]-5-[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)





RN 202853-06-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(1-naphthalenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-07-4 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(1-naphthalenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-08-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(2-naphthalenyl)-5-
 [[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-09-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(2-naphthalenyl)-5-
 [[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-10-9 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(3-methylphenyl)-5-
[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-11-0 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(3-methylphenyl)-5-
[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-12-1 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-
(9CI) (CA INDEX NAME)




RN 202853-13-2 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]-
(9CI) (CA INDEX NAME)




RN 202853-14-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI)
 (CA INDEX NAME)



RN 202853-16-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI)
 (CA INDEX NAME)




RN 202853-17-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-18-7 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-19-8 CAPLUS

CN 3-Pyridinemethanol, 2,6-dicyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-20-1 CAPLUS


CN 3-Pyridinemethanol, 2,6-dicyclopentyl-4-(4-fluorophenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-21-2 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202853-22-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-23-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-24-5 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[4-(trifluoromethyl)phenyl]methoxy]methyl- (9CI) (CA INDEX NAME)



RN 202857-35-0 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-cyclopentyl-2-ethyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 202862-11-1 CAPLUS


CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[1-(4-(trifluoromethyl)phenyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

fluorophenyl)ethoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 334931-56-5 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[2-(trifluoromethyl)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 334931-63-4 CAPLUS

CN 3-Pyridinemethanol, 5-[[[(3,4-dichlorophenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 334931-64-5 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[[(4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

36


Searched by Barb O'Bryen STIC 308-4291

REFERENCE(S): (1) Angerbauer; US 4988711 1991 CAPLUS
 (2) Angerbauer; US 5006530 1991 CAPLUS
 (3) Angerbauer; US 5169857 1992 CAPLUS
 (4) Angerbauer; US 5183897 1993 CAPLUS
 (5) Angerbauer; US 5401746 1995 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
 ACCESSION NUMBER: 2001:222007 CAPLUS
 DOCUMENT NUMBER: 134:252271
 TITLE: Preparation of tetrahydroquinolines and analogs as
 cholesteryl ester transfer protein inhibitors
 INVENTOR(S): Schmidt, Gunter; Brandes, Arndt; Angerbauer, Rolf;
 Logers, Michael; Muller-Gliemann, Matthias; Schmeck,
 Carsten; Bremm, Klaus-Dieter; Bischoff, Hilmar;
 Schmidt, Delf; Schuhmacher, Joachim; Giera, Henry;
 Paulsen, Holger; Naab, Paul; Conrad, Michael;
 Stoltefuss, Jurgen
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
 SOURCE: U.S., 124 pp., Cont.-in-part of U.S. 6,069,148.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6207671	B1	20010327	US 2000-521648	20000308
DE 19627419	A1	19980115	DE 1996-19627419	19960708
DE 19707199	A1	19980827	DE 1997-19707199	19970224
US 6069148	A	20000530	US 1997-889530	19970708
PRIORITY APPLN. INFO.:			DE 1996-19627419 A	19960708
			DE 1997-19707199 A	19970224
			US 1997-889530 A2	19970708

GI





AB The title compds. [I; A = (un)substituted aryl; D = (un)substituted aryl(alkyl), etc.; E = (cyclo)alkyl, (un)substituted Ph, etc.; R1R2 = substituted alkylene], useful in treating arteriosclerosis and/or dyslipidemia, were prepd. Thus, 1,3-cyclohexanedione was cyclocondensed with 4-FC6H4CHO and Me2CHCH(NH2):CHCO2Me and the product converted in 8 steps to title compd. II. Data for biol. activity of I were given.

IT 202203-35-8P 202203-36-9P 202203-37-0P
 202203-44-9P 202203-45-0P 202203-46-1P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tetrahydroquinolines and analogs as cholesteryl ester transfer protein inhibitors)



RN 202203-35-8 CAPLUS

CN 5-Quinolinol, 2,4-bis(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)





RN 202203-36-9 CAPLUS

CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-37-0 CAPLUS

CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-44-9 CAPLUS

CN 5-Quinolinol, 4-(4-fluorophenyl)-3-[[4-(fluorophenyl)methoxy]methyl]-
5,6,7,8-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202203-45-0 CAPLUS

CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202203-46-1 CAPLUS

CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3

REFERENCE(S): (1) Albert; US 4814346 1989 CAPLUS
 (2) Angerbauer; US 5006530 1991 CAPLUS
 (3) Angerbauer; US 5169857 1992 CAPLUS

L8 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3

ACCESSION NUMBER: 1998:427772 CAPLUS

DOCUMENT NUMBER: 129:95515

TITLE: Preparation of medium-ring polycyclic heterocycles as tachykinin receptor antagonists

INVENTOR(S): Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki; Ikeura, Yoshinori; Kimura, Chiharu; Tarui, Naoki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: U.S., 66 pp. Cont.-in-part of U.S. Ser. No. 621,360.

CODEN: USXXAM

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5770590	A	19980623	US 1996-717801	19960923
JP 09263585	A2	19971007	JP 1996-66337	19960322
JP 2976097	B2	19991110		
JP 09263587	A2	19971007	JP 1997-20386	19960322
CN 1140172	A	19970115	CN 1996-106081	19960323
US 5786352	A	19980728	US 1996-621360	19960325
US 6147071	A	20001114	US 1998-87894	19980601
PRIORITY APPLN. INFO.:			JP 1995-91436	A 19950324
			JP 1995-207553	A 19950720
			JP 1995-264727	A 19950918
			JP 1996-30033	A 19960123
			JP 1996-66337	A 19960322
			US 1996-621360	A2 19960325
			JP 1996-214698	A 19960814

OTHER SOURCE(S): MARPAT 129:95515
GI





AB A variety of polycyclic heterocycles are disclosed, and in particular the compds. I and salts are claimed [wherein X = O, S; Ar1, Ar2 = certain (un)substituted Ph; m, n = 0 to 4; (m+n) = 2 to 4; p = 1 to 6]. The compds. show an excellent tachykinin receptor antagonistic effect. For instance, (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]diazocino[2,1-g][1,7]naphthyridine, i.e., II [Y = absent, R = Me] (prepn. given) underwent hydroxylation by *Streptomyces subrutilus* IFO 13388 to give II [Y = absent, R = CH2OH] (III). The latter underwent acetylation with Ac2O and pyridine, N-oxidn. with m-ClC6H4C(O)OOH, and hydrolytic deacetylation, to give title compd. II [Y = O, R = CH2OH]. III had an ID50 of 2.5 .mu.g/kg i.v. for inhibiting capsaicin-induced tracheal plasma extravasation in anesthetized guinea pigs. I also showed substance P receptor antagonistic and NK2 receptor inhibitory activities.

IT 183550-95-0P 183551-05-5P 183551-08-8P
 183551-09-9P 183551-11-3P 183551-12-4P
 183551-16-8P 183551-20-4P 183551-21-5P
 183551-25-9P 183551-26-0P 183551-27-1P
 183551-28-2P 183551-29-3P 183551-30-6P
 183551-31-7P 183551-32-8P 183551-33-9P
 183551-34-0P 183551-35-1P 183551-36-2P
 183551-37-3P 183551-47-5P 183551-48-6P
 183551-49-7P 183551-50-0P 183551-56-6P
 183551-58-8P 183551-59-9P 183551-61-3P
 183551-67-9P 183551-68-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of medium-ring polycyclic heterocycles as tachykinin receptor antagonists)

RN 183550-95-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-05-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-aminoethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-08-8 CAPLUS
 CN Carbamic acid, [2-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(2-chloro-4-phenyl-3-pyridinyl)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 183551-09-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-11-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-12-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-16-8 CAPLUS



CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-20-4 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-(2-hydroxyethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-21-5 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-25-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 183551-26-0 CAPLUS


CN 2-Pyridinecarboxylic acid, 3-[[2-(2-hydroxyethyl)(phenylmethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-27-1 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-



(3-hydroxypropyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-28-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](3-hydroxypropyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 183551-29-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 183551-30-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dichlorophenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-31-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-32-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 183551-33-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(3-hydroxypropyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 183551-34-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-35-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183551-36-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-37-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-47-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-48-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183551-49-7 CAPLUS


CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-50-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 183551-56-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 183551-58-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-[(2R)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX



NAME)

Absolute stereochemistry.




RN 183551-59-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-61-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-67-9 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl-N3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-68-0 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N2-ethyl-N3-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4
 ACCESSION NUMBER: 1993:428008 CAPLUS
 DOCUMENT NUMBER: 119:28008
 TITLE: 7-(polysubstituted pyridyl)-6-heptenoates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
 INVENTOR(S): Angerbauer, Rolf; Fey, Peter; Huebsch, Walter; Philipps, Thomas; Bischoff, Hilmar; Petzinna, Dieter; Schmidt, Delf; Thomas, Guenter
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: U.S., 63 pp. Cont.-in-part of U.S. 5,006,530.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5169857	A	19921208	US 1990-627086	19901213
DE 3801406	A1	19890727	DE 1988-3801406	19880120
DD 283400	A5	19901010	DD 1989-325090	19890117
US 5006530	A	19910409	US 1989-298549	19890117
ZA 8900429	A	19900228	ZA 1989-429	19890119

Patel 09/922066

HU 52053 A2 19900628 HU 1989-5141 19890119
 US 5401746 A 19950328 US 1992-916928 19920720
 PRIORITY APPLN. INFO.: DE 1988-3801406 A 19880120
 IT 1988-21317 A 19880711
 US 1989-298549 A2 19890117
 US 1990-627086 A3 19901213

OTHER SOURCE(S):
 GI

CASREACT 119:28008; MARPAT 119:28008




I

AB Substituted pyridine derivs., (E)-3,5-dihydroxy-7-(4-phenyl-3-pyridyl)-6-heptenoates, are claimed. The use of these compds. for the treatment of hyperlipoproteinemia, lipoproteinemia, or arteriosclerosis is claimed. Also claimed is Me (E)-erythro-7-[2-(4-fluorophenyl)-4-isopropyl-5-(methoxymethyl)-6-methyl-3-pyridyl]-3,5-dihydroxy-6-heptenoate (I). I was prepd. from Et 2-(4-fluorophenyl)-5-(methoxymethyl)-6-methyl-3-pyridinecarboxylate. The compds. thus prepd. are inhibitors of cholesterol synthesis (no data).

IT 124863-93-0P 124864-31-9P 124864-38-6P
 124864-80-8P 148040-57-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as anticholesteremic and antiarteriosclerotic)

RN 124863-93-0 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 124864-31-9 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Searched by Barb O'Bryen STIC 308-4291

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-38-6 CAPLUS
CN 6-Heptenoic acid, 7-[5-[(benzoyloxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-80-8 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-1-oxido-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 148040-57-7 CAPLUS
CN 6-Octenoic acid, 7-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 148040-52-2P 148040-58-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for dihydroxy(phenylpyridyl)heptenoate
(anticholesteremic and antiarteriosclerotic))

RN 148040-52-2 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]-3-pyridinyl]-1-propenyl]tetrahydro-4-hydroxy-,
[4.alpha.,6.beta.(E)]- (9CI) (CA INDEX NAME)



RN 148040-58-8 CAPLUS

CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5-[[4-
fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-1-
propenyl]tetrahydro-4-hydroxy-, [4.alpha.,6.beta.(E)]- (9CI) (CA INDEX
NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 124863-88-3 124863-89-4 124863-90-7


124863-91-8 148040-15-7

RL: RCT (Reactant)

(reactant for dihydroxy(phenylpyridyl)heptenoate (anticholesteremic and antiarteriosclerotic))


RN 124863-88-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 124863-89-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 124863-90-7 CAPLUS
 CN 3-Pyridinecarboxaldehyde, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 124863-91-8 CAPLUS
 CN 2-Propenal, 3-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 148040-15-7 CAPLUS

L8 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:396485 CAPLUS

DOCUMENT NUMBER: 135:5533

TITLE: Process for preparation of pyridine derivatives

INVENTOR(S): Hilpert, Hans; Hoffmann-Emery, Fabienne; Rimmeler,
 Goesta; Rogers-Evans, Mark; Stahr, Helmut Werner;
 Waldmeier, Pius

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1103546	A1	20010530	EP 2000-125665	20001123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6303790	B1	20011016	US 2000-716538	20001120
JP 2001151755	A2	20010605	JP 2000-360682	20001128

CN 1297887 A 20010606 CN 2000-128383 20001128
 PRIORITY APPLN. INFO.: EP 1999-123686 A 19991129
 OTHER SOURCE(S): MARPAT 135:5533
 GI




AB The title compds. [I; R1 = alkyl, (un)substituted aryl; R2, R22 = H, halo, CF3, etc.; R2 and R22 may be together = (un)substituted CH:CHCH:CH; R3, R33 = H, alkyl, or forming a cycloalkyl together with the carbon atom, to which they are attached; R4 = H, alkyl, (un)substituted NH2, etc.; X = CONR5, NR5CO; R5 = H, alkyl, CH2Ph; n = 0-4], useful as antagonists of neurokinin 1 receptor (no data), were prepd. Thus, treating 6-chloronicotinic acid with SOCl2 and MeNH2.HCl followed by reaction of 6-chloro-N-methylnicotinamide with o-tolylmagnesium chloride and 1-methylpiperazine, treatment of 6-(4-methylpiperazin-1-yl)-4-o-tolyl-4,5-dihydropyridine-3-carboxylic acid methylamide with MnO2, and reacting N-methyl-6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide with 3,5-bis(trifluoromethyl)benzyl bromide afforded the nicotinamide II.

IT **342417-03-2P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (process for prepn. of pyridine derivs.)

RN 342417-03-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-4-(2-methylphenyl)-N-(phenylmethyl)- (9CI)
 (CA INDEX NAME)




IT 290296-68-3P 290297-57-3P 342416-86-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepn. of pyridine derivs.)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 342416-86-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-(2-methylphenyl)-6-(4-morpholinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

REFERENCE(S):

3

(1) La Roche, H; EP 1035115 A 2000 CAPLUS

(2) Schlecker, W; TETRAHEDRON 1995, V51(35), P9531

CAPLUS

(3) Warner Lambert Co; EP 0235663 A 1987 CAPLUS

L8 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:396484 CAPLUS

DOCUMENT NUMBER: 135:5620

TITLE: Preparation of 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-[6-(morpholin-4-yl)-4-(o-tolyl)-pyridin-3-yl]-isobutyramide for the treatment of diseases related to the NK-1 receptor

INVENTOR(S): Ballard, Theresa Maria; Higgins, Guy Andrew; Hoffmann, Torsten; Poli, Sonia Maria; Sleight, Andrew

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1103545	A1	20010530	EP 2000-125450	20001121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
GB 2356863	A1	20010606	GB 2000-28566	20001123
DE 10058310	A1	20010531	DE 2000-10058310	20001124
FR 2801590	A1	20010601	FR 2000-15193	20001124
JP 2001151754	A2	20010605	JP 2000-356833	20001124
NO 2000006012	A	20010530	NO 2000-6012	20001128
BR 2000005616	A	20010717	BR 2000-5616	20001128
CN 1297888	A	20010606	CN 2000-134260	20001129
PRIORITY APPLN. INFO.: GI			EP 1999-123685	A 19991129



I

AB The title compd. I which is a potent and selective antagonist at recombinant human neurokinin1 (NK1) receptors expressed in CHO cells, was prepd. (details of multi-step synthesis were given) and formulated. The compd. I showed an affinity (pKi) of 9.0 for the human NK1 receptor over 2 orders of magnitude of selectivity for the NK1 receptor compared to NK2 and NK3 receptors and compared to over 50 other binding sites that have been evaluated.


IT 290296-68-3P 341023-51-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-[6-(morpholin-4-yl)-4-(o-tolyl)-pyridin-3-yl]-isobutyramide for the treatment of diseases related to the NK-1 receptor)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 341023-51-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

2

REFERENCE(S):

- (1) Glaxo Group Ltd; EP 0916346 A 1999 CAPLUS
- (2) La Roche, H; EP 1035115 A 2000 CAPLUS

L8 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:192959 CAPLUS

DOCUMENT NUMBER: 135:158

TITLE: Mapping and fitting the peripheral benzodiazepine receptor binding site by carboxamide derivatives. comparison of different approaches to quantitative ligand-receptor interaction modeling

AUTHOR(S):

Anzini, Maurizio; Cappelli, Andrea; Vomero, Salvatore; Seeber, Michele; Menziani, Maria Cristina; Langer, Thierry; Hagen, Bertram; Manzoni, Cristina; Bourguignon, Jean-Jacques

CORPORATE SOURCE:

Dipartimento di Scienze Farmacobiologiche, Universita degli Studi Magna Graecia di Catanzaro, Catanzaro, 88021, Italy

SOURCE:

J. Med. Chem. (2001), 44(8), 1134-1150
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB The synthetic-computational approach to the study of the binding site of

peripheral benzodiazepine receptor (PBR) ligands related to 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK11195) within their receptor (Cappelli et al. J. Med. Chem. 1997, 40, 2910-2921) has been extended. A series of carboxamide derivs. endowed with differently substituted planar arom. or heteroarom. systems was designed with the aim of getting further information on the topol. requisites of the carbonyl and arom. moieties for interaction with the PBR binding site. The synthesis of most of these compds. involves Weinreb amidation of the appropriate lactone as the key step. The most potent compd., among the newly synthesized ones, shows a nanomolar PBR affinity similar to that shown by 1 and the presence of a basic N-ethyl-N-benzylaminomethyl group in 3-position of the quinoline nucleus. Thus, it may be considered the first example of a new class of water sol. derivs. of PK11195. Several computational methods were used to furnish descriptors of the isolated ligands (indirect approaches) able to rationalize the variation in the binding affinity of the enlarged series of compds. Sound QSAR models are obtained by size and shape descriptors (vol. approach) which codify for the short-range contributions to ligand-receptor interactions. Mol. descriptors which explicitly account for the electrostatic contribution to the interaction (CoMFA, CoMSIA, and surface approaches) perform well, but they do not improve the quant. models. Moreover, useful hints for the identification of the antagonist binding site in the three-dimensional modeling of the receptor (direct approach) were provided by the receptor hypothesis derived by the pharmacophoric approach. The ligand-receptor complexes obtained provided a detailed description of the modalities of the interaction and interesting suggestions for further expts.


IT 342011-42-1P 342011-61-4P

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(mapping and fitting peripheral benzodiazepine receptor binding site by carboxamide derivs.: quant. ligand-receptor interaction modeling)


RN 342011-42-1 CAPLUS

CN 3-Quinolinecarboxamide, 2-[[ethyl(phenylmethyl)amino]methyl]-N,4-diphenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 342011-61-4 CAPLUS

CN 2-Quinolinecarboxamide, N,N-diethyl-3-[[ethyl(phenylmethyl)amino]methyl]-4-phenyl- (9CI) (CA INDEX NAME)




IT 342011-75-0P 342011-95-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (mapping and fitting peripheral benzodiazepine receptor binding site by
 carboxamide derivs.: quant. ligand-receptor interaction modeling)


RN 342011-75-0 CAPLUS

CN 3-Quinolinecarboxamide, 2-(hydroxymethyl)-4-phenyl-N-(phenylmethyl)- (9CI)
 (CA INDEX NAME)



RN 342011-95-4 CAPLUS

CN 3-Quinolinecarboxamide, 2-(chloromethyl)-4-phenyl-N-(phenylmethyl)- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT:

43

REFERENCE(S):

- (1) Anzini, M; Farmaco 1992, V47, P191 CAPLUS
 - (2) Anzini, M; Heterocycles 1994, V38, P103 CAPLUS
 - (4) Bernassau, J; J Mol Graphics 1993, V11, P236 CAPLUS
 - (5) Bourguignon, J; Peripheral Benzodiazepine Receptors 1993, P59 CAPLUS
 - (6) Bowie, J; Science 1991, V253, P164 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:383926 CAPLUS

DOCUMENT NUMBER: 133:17490

TITLE: Preparation of [1,4]diazepino[2,1-g][1,7]naphthyridine, [1,4]diazonino[2,1-g][1,7]naphthyridine, 13H-[1,4]diazocino[2,1-g][1,7]naphthyridine, and pyrido[3,2-f][1,4]oxazepine derivatives and related compounds as antiemetics

INVENTOR(S): Doi, Takayuki; Yamamoto, Masaki; Fukui, Hideo

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 284 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032192	A1	20000608	WO 1999-JP6569	19991125
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK,				

SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1145714 A1 20011017 EP 1999-972920 19991125
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2000273042 A2 20001003 JP 1999-336187 19991126
 JP 1998-337438 A 19981127
 JP 1999-10907 A 19990119
 WO 1999-JP6569 W 19991125
 PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 133:17490

GI For diagram(s), see printed CA Issue.

AB Drugs comprising compds. represented by general formula (I) (wherein the ring M is a heterocycle having, as the partial structure X:Y, N:C, CO-N or CS-N; Ra and Rb are bonded to each other to form the ring A, or Ra and Rb are the same or different and each represents hydrogen or a substituent of the ring M; the rings A and B are each an optionally substituted homocyclic or heterocycle and at least one of them is an optionally substituted heterocycle; the ring C is an optionally substituted homocyclic or heterocycle; the ring Z is an optionally substituted nitrogen-contg. heterocycle; and n is an integer of 1 to 6) or salts thereof combined with emetic drugs are claimed. The compds. I or salts thereof are useful as antiemetic agents which, in particular, can rapidly and safely inhibit even at a small dose emesis induced by emetic drugs such as anticancer agents, morphine, and apomorphine. Thus, a mixt. of (R)-N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(4-hydroxy-3-methylbutyl)-5-(4-methylphenyl)-8-oxo-6-pyrido[3,4-b]pyridinecarboxamide (prepn. given), Et₃N, and MeSO₂Cl in THF was stirred at room temp. for 30 min, followed by treatment of the product with NaH in THF at room temp. for 1.5 h to give (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]diazocino[2,1-g][1,7]naphthyridine (II). II at 1-10 mg/kg p.o. in vivo inhibited cisplatin-induced emesis in male ferret. Pharmaceutical formulations contg. I were prepd.


IT 183551-50-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 13H-[1,4]diazocino[g][1,7]naphthyridine derivs. and related compds. as antiemetics)

RN 183551-50-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 183550-95-0P 183551-05-5P 183551-09-9P
 183551-11-3P 183551-12-4P 183551-16-8P
 183551-20-4P 183551-21-5P 183551-25-9P
 183551-26-0P 183551-27-1P 183551-28-2P
 183551-29-3P 183551-30-6P 183551-31-7P
 183551-32-8P 183551-34-0P 183551-35-1P
 183551-36-2P 183551-37-3P 183551-47-5P
 183551-48-6P 183551-49-7P 183551-56-6P
 183551-58-8P 183551-59-9P 183551-61-3P
 183551-67-9P 183551-68-0P 272436-92-7P
 272436-94-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of 13H-[1,4]diazocino[g][1,7]naphthyridine derivs. and related
 compds. as antiemetics)


RN 183550-95-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-05-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-aminoethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-09-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-11-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-12-4 CAPLUS



CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-16-8 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-20-4 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-21-5 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-25-9 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-26-0 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[[[(2-hydroxyethyl)(phenylmethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-27-1 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-



(3-hydroxypropyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-28-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](3-hydroxypropyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 183551-29-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 183551-30-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dichlorophenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-31-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-32-8 CAPLUS


CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-34-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-35-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-36-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-37-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-47-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-48-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183551-49-7 CAPLUS


CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-56-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.





RN 183551-58-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-[(2R)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.




RN 183551-59-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(2-hydroxyethyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-61-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-67-9 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl-N3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 183551-68-0 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N2-ethyl-N3-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 272436-92-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl)methyl]-2-chloro-N-[2-[(1,1-dimethylethoxy)formylamino]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 272436-94-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxypropyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:
 REFERENCE(S):


- 11
 (1) Glaxo Group Ltd; JP 06107563 A CAPLUS
 (2) Glaxo Group Ltd; US 5360820 A CAPLUS
 (3) Glaxo Group Ltd; US 5547964 A CAPLUS
 (5) Glaxo Group Ltd; EP 533280 A1 1993 CAPLUS
 (6) Glaxo Group Ltd; EP 615751 A1 1994 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2002 ACS

Searched by Barb O'Bryen STIC 308-4291

ACCESSION NUMBER: 2000:607348 CAPLUS
 DOCUMENT NUMBER: 133:207811
 TITLE: Preparation of N-benzyl-4-tolylnicotinamides and related compounds as neurokinin-1 receptor antagonists.
 INVENTOR(S): Boes, Michael; Branca, Quirico; Galley, Guido; Godel, Thierry; Hoffmann, Torsten; Hunkeler, Walter; Schnider, Patrick; Stadler, Heinz
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
 SOURCE: Ger. Offen., 38 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10008042	A1	20000831	DE 2000-10008042	20000222
EP 1035115	A1	20000913	EP 2000-102260	20000215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
GB 2347422	A1	20000906	GB 2000-3908	20000218
FR 2790473	A1	20000908	FR 2000-2170	20000222
US 6297375	B1	20011002	US 2000-507456	20000222
NO 2000000885	A	20000825	NO 2000-885	20000223
BR 2000000908	A	20000912	BR 2000-908	20000223
CN 1270959	A	20001025	CN 2000-102401	20000223
JP 2000247957	A2	20000912	JP 2000-47003	20000224
PRIORITY APPLN. INFO.:			EP 1999-103504	A 19990224
OTHER SOURCE(S):			EP 1999-123689	A 19991129
GI			MARPAT 133:207811	




AB Title compds. [I; R = H, alkyl, alkoxy, halo, CF₃; R₁ = H, halo; RR₁ = CH:CHCH:CH; R₂, R₂₁ = H, halo, CF₃, alkoxy, cyano; R₂R₂₁ = (substituted) CH:CHCH:CH; R₃ = H, alkyl, cycloalkyl; R₄ = H, N(R₅)₂, N(R₅)(CH₂)nOH, N(R₅)S(O)₂A, N(R₅)S(O)₂Ph, N:CHN(R₅)₂, N(R₅)C(O)R₅, specified cyclic tertiary amine; R₅ = H, cycloalkyl, benzyl, alkyl; X = C(O)N(R₅), (CH₂)mO, (CH₂)mN(R₅), N(R₅)C(O), N(R₅)(CH₂)m; n = 0-4; m = 1, 2], were prepd. Thus, 4-o-tolylnicotinic acid (prepn. given) was stirred with SOCl₂ and cat. DMF in CH₂Cl₂ to give a residue which was refluxed with N-[3,5-bis(trifluoromethyl)benzyl]-N-methylamine and Et₃N in PhMe to give 67% N-(3,5-bistrifluoromethylbenzyl)-N-methyl-4-o-tolylnicotinamide. Tested I antagonized NK-1 receptors with pK_i = 8.20-9.54.
 IT 290297-14-2P 290297-18-6P 290297-26-6P 290297-30-2P
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-benzyl-4-tolynicotinamides and related compds. as neurokinin-1 receptor antagonists)


RN 290297-14-2 CAPLUS
 CN Benzeneacetamide, N-[6-amino-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-18-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290297-26-6 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290297-30-2 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 290296-41-2P 290296-42-3P 290296-43-4P
 290296-44-5P 290296-45-6P 290296-46-7P
 290296-47-8P 290296-48-9P 290296-49-0P
 290296-50-3P 290296-51-4P 290296-52-5P
 290296-53-6P 290296-54-7P 290296-55-8P
 290296-56-9P 290296-57-0P 290296-58-1P
 290296-59-2P 290296-60-5P 290296-61-6P
 290296-62-7P 290296-63-8P 290296-65-0P
 290296-66-1P 290296-67-2P 290296-68-3P
 290296-69-4P 290296-70-7P 290296-71-8P
 290296-72-9P 290296-73-0P 290296-74-1P
 290296-75-2P 290296-76-3P 290296-77-4P
 290296-78-5P 290296-79-6P 290296-80-9P
 290296-81-0P 290296-82-1P 290296-83-2P
 290296-84-3P 290296-85-4P 290296-86-5P
 290296-87-6P 290296-88-7P 290296-89-8P
 290296-90-1P 290296-91-2P 290296-92-3P
 290296-93-4P 290296-94-5P 290296-95-6P
 290296-96-7P 290296-98-9P 290296-99-0P
 290297-00-6P 290297-01-7P 290297-02-8P
 290297-03-9P 290297-04-0P 290297-05-1P
 290297-06-2P 290297-07-3P 290297-08-4P
 290297-09-5P 290297-10-8P 290297-11-9P
 290297-12-0P 290297-13-1P 290297-15-3P
 290297-16-4P 290297-17-5P 290297-57-3P
 290297-59-5P 290297-60-8P 290297-61-9P
 290297-62-0P 290297-63-1P 290297-64-2P
 290297-65-3P 290297-66-4P 290298-21-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of N-benzyl-4-tolylnicotinamides and related compds. as neurokinin-1 receptor antagonists)

RN 290296-41-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-42-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-43-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 290296-44-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-45-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-46-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 290296-47-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-ethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-48-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 290296-49-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-50-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-difluorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-51-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-52-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 290296-53-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 290296-54-7 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 290296-55-8 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 290296-56-9 CAPLUS
 CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




2 HCl

RN 290296-57-0 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 290296-58-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 290296-59-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-60-5 CAPLUS
 CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 290296-61-6 CAPLUS
 CN Benzeneacetamide, N,.alpha.-dimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 290296-62-7 CAPLUS
 CN Cyclopropanecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-3-pyridinyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 290296-63-8 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, hydrochloride (2:3) (9CI) (CA INDEX NAME)




● 3/2 HCl

RN 290296-65-0 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 290296-66-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-67-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-68-3 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-69-4 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 290296-70-7 CAPLUS
 CN Benzeneacetamide, N-[6-(dimethylamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-71-8 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-72-9 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-73-0 CAPLUS
 CN Benzeneacetamide, N-[6-(4-hydroxy-1-piperidiny)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-74-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.




RN 290296-75-2 CAPLUS
 CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-76-3 CAPLUS
 CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290296-77-4 CAPLUS
 CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-78-5 CAPLUS


CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 290296-79-6 CAPLUS

CN 3-Pyridinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-80-9 CAPLUS

CN Pyridine, 3-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)





RN 290296-81-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 290296-82-1 CAPLUS
 CN 3-Pyridinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 290296-83-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]pyridin-2-yl]-N-methyl-6-(4-methyl-1-piperazinyl)-1-naphthalenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

1[methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 290296-84-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 290296-85-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 290296-86-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)



RN 290296-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)

NAME)




RN 290296-95-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-96-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-cyanoethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-98-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1,2,4-oxadiazol-3-ylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 290296-99-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-((2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl)-1-piperazinyl]-N-methyl-

4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-01-7 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-02-8 CAPLUS


CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 290297-03-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-04-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-05-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-06-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chloro-5-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-07-3 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 290297-08-4 CAPLUS


CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-09-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-


yl]phenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI)
(CA INDEX NAME)




RN 290297-10-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-11-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290297-12-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1H-tetrazol-5-ylmethyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 290297-13-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-
 [(phenylmethyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA
 INDEX NAME)




RN 290297-15-3 CAPLUS
 CN Benzeneacetamide, N-[6-[[[(dimethylamino)methylene]amino]-4-(2-
 methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-
 bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-16-4 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-
 [(methylsulfonyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA
 INDEX NAME)




RN 290297-17-5 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-
 [(phenylsulfonyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA
 INDEX NAME)




RN 290297-57-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290297-59-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 290297-60-8 CAPLUS
 CN 4-Piperidineacetic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290297-61-9 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)


RN 290297-62-0 CAPLUS

CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-63-1 CAPLUS

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-64-2 CAPLUS


CN Benzeneacetamide, N,.alpha.-dimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-65-3 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)



RN 290297-66-4 CAPLUS
 CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-
 fluoro-2-methylphenyl)-N-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA
 INDEX NAME)



RN 290298-21-4 CAPLUS
 CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-
 pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




IT 290297-47-1

RL: RCT (Reactant)

(prepn. of N-benzyl-4-tolynicotinamides and related compds. as neurokinin-1 receptor antagonists)

RN 290297-47-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 290297-31-3P 290297-41-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of N-benzyl-4-tolynicotinamides and related compds. as neurokinin-1 receptor antagonists)


RN 290297-31-3 CAPLUS

CN Cyclopropanecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-3-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 290297-41-5 CAPLUS

CN Carbamic acid, [5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:613656 CAPLUS

DOCUMENT NUMBER: 131:228734

TITLE: Preparation of diazocinonaphthyridines, diazepinonaphthyridines, and related compounds having tachykinin receptor antagonistic activity for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.

INVENTOR(S): Natsugari, Hideaki; Doi, Takayuki; Ikeura, Yoshinori

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 207 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947132	A2	19990923	WO 1999-JP1358	19990318
WO 9947132	A3	19991111		
W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9928532	A1	19991011	AU 1999-28532	19990318
JP 11322748	A2	19991124	JP 1999-72954	19990318
BR 9908895	A	20001205	BR 1999-8895	19990318
EP 1061926	A2	20001227	EP 1999-909233	19990318
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
NO 2000004144	A	20001010	NO 2000-4144	20000818
PRIORITY APPLN. INFO.:			JP 1998-69999	A 19980319
			WO 1999-JP1358	W 19990318
OTHER SOURCE(S):		MARPAT 131:228734		
GI				



AB Pharmaceutical compns. for preventing or treating depression, anxiety, manic-depression, or psychopathy [I; XY = N:C, CON, CSN; Ra, Rb = H, substituent; RaRb = atoms to form a (substituted) (heterocyclic) ring; B, E = (substituted) homocyclic or heterocyclic ring, Z = (substituted) N-contg. heterocyclic ring; n = 1-6; with provisos], are claimed. Thus, (9R)-7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9,10,11-hexahydro-9-methyl-5-(4-methylphenyl)-6,13-dioxo-13H-[1,4]-diazocino[2,1-g][1,7]naphthyridine (II) (prepn. described) antagonized substance P with IC50 = 0.43 nM. A II tablet formulation is given.



IT 183550-95-0P 183551-05-5P 183551-09-9P
183551-11-3P 183551-12-4P 183551-16-8P
183551-21-5P 183551-50-0P 183551-56-6P
183551-59-9P 183551-61-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diazocinonaphthyridines, diazepinonaphthyridines, and related compds. having tachykinin receptor antagonistic activity)


RN 183550-95-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl)methyl]-2-chloro-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-05-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-aminoethyl)-N-[[3,5-bis(trifluoromethyl)phenyl)methyl]-2-chloro-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-09-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-11-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-12-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-16-8 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-21-5 CAPLUS


CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-50-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 183551-56-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-59-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-61-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-

N-(3-hydroxypropyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)




IT 183551-67-9 183551-68-0

RL: RCT (Reactant)

(prepn. of diazocinonaphthyridines, diazepinonaphthyridines, and related compds. having tachykinin receptor antagonistic activity)



RN 183551-67-9 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl-N3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-68-0 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N2-ethyl-N3-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



IT 183551-08-8P 183551-20-4P 183551-25-9P
 183551-26-0P 183551-27-1P 183551-28-2P
 183551-29-3P 183551-30-6P 183551-31-7P
 183551-32-8P 183551-33-9P 183551-34-0P


183551-35-1P 183551-36-2P 183551-37-3P

183551-47-5P 183551-48-6P 183551-49-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of diazocinonaphthyridines, diazepinonaphthyridines, and
 related compds. having tachykinin receptor antagonistic activity)



RN 183551-08-8 CAPLUS

CN Carbamic acid, [2-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(2-chloro-4-phenyl-3-pyridinyl)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME).





RN 183551-20-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-25-9 CAPLUS


CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-26-0 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[[[(2-hydroxyethyl)(phenylmethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-27-1 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(3-hydroxypropyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-28-2 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(3-hydroxypropyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-29-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 183551-30-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dichlorophenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-31-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-32-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-33-9 CAPLUS


CN 3-Pyridinecarboxamide, 2-chloro-N-(3-hydroxypropyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 183551-34-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-35-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl-

N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-36-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-37-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-47-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-48-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
N-(2-hydroxyethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183551-49-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:529133 CAPLUS

DOCUMENT NUMBER: 131:157711

DOCUMENT NUMBER: 151.157711
 TITLE: Preparation of pyridinecarboxylates and analogs as
 cholesteryl ester transfer protein inhibitors
 INVENTOR(S):

INVENTOR(S): cholesteryl ester transfer protein inhibitors
Lee, Len F.; Glenn, Kevin C.; Connolly, Daniel T.;
Corley, David G.; Flynn, Daniel L.; Hamme, Ashton;
Hegde, Shridhar G.; Melton, Michele A.; Schilling,
Roger J.; Sikorski, James A.; Wall, Nancy N.;
Zablocki, Jeffrey A.

PATENT ASSIGNEE(S): ZABLOCKI, Jeffrey A.
G.D. Searle & Co., USA

SOURCE: G.D. Searle & Co., USA
PCT Int. Appl., 327 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

Searched by Barb O'Bryen STIC 308-4291

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9941237	A1	19990819	WO 1999-US1871	19990211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932854	A1	19990830	AU 1999-32854	19990211
PRIORITY APPLN. INFO.:			US 1998-74586	P 19980213
			WO 1999-US1871	W 19990211
OTHER SOURCE(S):			MARPAT 131:157711	
GI				




AB Title compds. [I; R2, R6 = H, OH, (fluoro)alkyl, alkoxy, etc.; R3 = OH, CHO, alkoxy, carbonyl, (hetero)arylcarbonyl, etc.; R5 = H, halo, alkyl, alkoxy, etc.; R5 = H, halo, alkyl, alkoxy(carbonyl), etc.] were prep'd. Thus, CF₃C(NH₂):C(CO₂Me)COMe was refluxed with Ac₂O/HC(OMe)₃ and the product converted in 2 steps to I (R2 = CF₃, R3 = CO₂Me, R4 = OCHMe₂, R5 = R6 = H). Data for biol. activity of I were given.

IT 237759-36-3P 237759-40-9P 237759-64-7P
237759-65-8P 237759-69-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridinecarboxylates and analogs as cholesteryl ester transfer protein inhibitors)


RN 237759-36-3 CAPLUS

CN Pyridine, 2-(difluoromethyl)-4-(4-fluorophenyl)-3-[fluoro[4-(trifluoromethyl)phenyl]methyl]-5-[(phenylmethoxy)methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 237759-40-9 CAPLUS

CN 3-Pyridinecarboxaldehyde, 2-(difluoromethyl)-4-(4-fluorophenyl)-5-[(phenylmethoxy)methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)





RN 237759-64-7 CAPLUS

CN 3-Pyridinemethanol, 2-(difluoromethyl)-4-(4-fluorophenyl)-5-
[(phenylmethoxy)methyl]-6-(trifluoromethyl)-.alpha.-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 237759-65-8 CAPLUS

CN Pyridine, 2-(difluoromethyl)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]met
hyl]-4-(4-fluorophenyl)-5-[(phenylmethoxy)methyl]-6-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



RN 237759-69-2 CAPLUS

CN 3-Pyridinemethanol, 2-(difluoromethyl)-4-(4-fluorophenyl)-5-
[(phenylmethoxy)methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

29

REFERENCE(S):

- (1) Bayer Ag; EP 0796846 A 1997 CAPLUS
 - (2) Bayer Ag; EP 0818197 A 1998 CAPLUS
 - (3) Bayer Ag; WO 9804528 A 1998 CAPLUS
 - (4) Hegde, S; JOURNAL OF ORGANIC CHEMISTRY 1991, V56(19), P5726 CAPLUS
 - (5) Korte, D; US 5125956 A 1992 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:172594 CAPLUS

DOCUMENT NUMBER: 130:223174

TITLE: Preparation of 4-aryl-3-aminoquinoline-2-ones as potassium channel modulators

INVENTOR(S): Hewawasam, Piyasena; Starrett, John E., Jr.; Swartz, Stephen G.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909983	A1	19990304	WO 1998-US17508	19980824
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9891169	A1	19990316	AU 1998-91169	19980824
US 5972961	A	19991026	US 1998-138638	19980824
EP 1011677	A1	20000628	EP 1998-943348	19980824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513560	T2	20010904	JP 2000-507373	19980824
PRIORITY APPLN. INFO.: US 1997-58014 P 19970828				
WO 1998-US17508 W 19980824				
OTHER SOURCE(S): MARPAT 130:223174				
GI				




AB The title compds. [I; R, R1 = H, Me; R2-R4 = H, halo, NO2, CF3; R5 = H, alkyl, alkylsulfonyl, etc.; R6 = H, Br, Cl, NO2] which are modulators of the large conductance calcium-activated K⁺ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels such as ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, male erectile dysfunction, and urinary incontinence, were prepd. Thus, demethylation of 3-amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one (prepn. given) with BBr₃ in CH₂Cl₂ afforded 97% I [R1 = H; R2 = R4 = H; R3 = CF₃; R5 = H; R6 = Cl; RO = 2-OH] which showed > 150% increase over BK current in controls at 20 .mu.M.

IT **221112-59-0P 221112-61-4P 221112-71-6P**
221112-72-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 4-aryl-3-aminoquinoline-2-ones as potassium channel modulators)


RN 221112-59-0 CAPLUS

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 221112-61-4 CAPLUS

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 221112-71-6 CAPLUS

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 221112-72-7 CAPLUS

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]-4-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

REFERENCE(S):

- (1) Brust; US 3202661 A 1965 CAPLUS
- (2) Hewawasam; US 5565483 A 1996 CAPLUS
- (3) Meguro; US 5223513 A 1993 CAPLUS

L8 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:727418 CAPLUS

DOCUMENT NUMBER: 132:3329

TITLE: Solid-phase synthesis of pyrrolo[3,4-b]pyridines and related pyridine-fused heterocycles

AUTHOR(S): Bhandari, Ashok; Li, Bei; Gallop, Mark A.


CORPORATE SOURCE: Affymax Research Institute, Santa Clara, CA, 95051, USA

SOURCE: Synthesis (1999), (11), 1951-1960

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Sequential Hantzsch condensation and cyclative cleavage reactions were used to define a novel solid-phase route to pyrrolo[3,4-b]pyridines and related pyridine-fused heterocycles. A combinatorial library of .apprx.5000 compds. prepd. via this chem. is described.
 IT 251299-89-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of libraries of pyrrolopyridines and related pyridine-fused heterocycles)
 RN 251299-89-5 CAPLUS
 CN 1,6-Naphthyridine-3-carboxamide, 4-(3,4-dichlorophenyl)-5,6,7,8-tetrahydro-5-oxo-N,2-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9
 REFERENCE(S):
 (1) Anzini, M; J Heterocyclic Chem 1992, V29, P1111 CAPLUS
 (2) Anzini, M; J Med Chem 1996, V39, P4275 CAPLUS
 (3) Gordeev, M; Tetrahedron Lett 1996, V37, P4643 CAPLUS
 (4) Matsuo, K; Chem Express 1992, V7, P465 CAPLUS
 (5) Smrcina, M; Tetrahedron 1997, V53, P12867 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L8 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:234534 CAPLUS
 DOCUMENT NUMBER: 131:53561
 TITLE: Novel Potent and Selective Central 5-HT3 Receptor Ligands Provided with Different Intrinsic Efficacy. 2. Molecular Basis of the Intrinsic Efficacy of Arylpiperazine Derivatives at the Central 5-HT3 Receptors
 AUTHOR(S): Cappelli, Andrea; Anzini, Maurizio; Vomero, Salvatore; Canullo, Laura; Mennuni, Laura; Makovec, Francesco; Doucet, Edith; Hamon, Michel; Menziani, M. Cristina; De Benedetti, Pier G.; Bruni, Giancarlo; Romeo, Maria R.; Giorgi, Gianluca; Donati, Alessandro
 CORPORATE SOURCE: Dipartimento Farmaco Chimico Tecnologico, Universita di Siena, Siena, 53100, Italy
 SOURCE: J. Med. Chem. (1999), 42(9), 1556-1575
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Novel 5-HT3 receptor ligands were designed and synthesized with the aim of obtaining deeper insight into the mol. basis of the intrinsic efficacy of arylpiperazines interacting with the central 5-HT3 receptor. The newly synthesized compds. and some previously published compds. belonging to the same class of heteroarylpiperazines were tested for their potential

ability to displace [3H]granisetron from rat cortical membranes. These 5-HT₃ receptor binding studies revealed subnanomolar affinity in several of the compds. under study. The most active ligands were quipazine derivs. bearing a Ph group in the 4-position and various oxygenated alkyl side chains in the 3-position of the quinoline nucleus. Qual. and theor. quant. structure-affinity relation studies were carried out, and the interaction model for the 5-HT₃ ligands related to quipazine with their receptor, proposed in part 1 of the present work, was updated to incorporate the latest data. The potential 5-HT₃ agonist/antagonist activity of 12 selected compds. was assessed in vitro on the 5-HT₃ receptor-dependent [14C]guanidinium uptake in NG 108-15 cells. Their intrinsic efficacy ranged from the 5-HT₃ full agonist properties to those of partial agonists and antagonists. The comparison between these functional data and those relative to the previously described compds. suggested that in this class of 5-HT₃ ligands the intrinsic efficacy is modulated in a rather subtle manner by the steric features of the heteroaryl moiety.


IT 140842-11-1

RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)

(prepn. and QSAR of arylpiperazines as central 5-HT₃ receptor ligands)

RN 140842-11-1 CAPLUS

CN 3-Quinolinemethanol, 2-(4-methyl-1-piperazinyl)-4-phenyl-, benzoate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT:
REFERENCE(S):

- 53
(2) Anzini, M; Heterocycles 1993, V36, P1065 CAPLUS
(3) Anzini, M; J Med Chem 1995, V38, P2692 CAPLUS
(4) Barnes, J; Nature 1989, V338, P762 CAPLUS
(5) Blandina, P; Eur J Pharmacol 1988, V155, P349 CAPLUS
(6) Bolanos, F; Biochem Pharmacol 1990, V40, P1541 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:105938 CAPLUS

DOCUMENT NUMBER: 128:167354

TITLE: Preparation of substituted pyridines and biphenyls as anti-hypercholesteremic, anti-hyperlipoproteinemic and anti-hyperglycemic agents

INVENTOR(S): Schmidt, Gunter; Angerbauer, Rolf; Brandes, Arndt; Muller-Gliemann, Matthias; Bischoff, Hilmar; Schmidt, Delf; Wohlfeil, Stefan; Schoen, William R.; Ladouceur, Gaetan H.; Cook, James H., II; Lease, Timothy G.; Wolanin, Donald J.; Kramss, Richard H.; Hertzog, Donald L.; Osterhout, Martin H.





PATENT ASSIGNEE(S): Bayer Corporation, USA; Bayer Aktiengesellschaft
SOURCE: PCT Int. Appl., 431 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804528	A2	19980205	WO 1997-US13248	19970729
WO 9804528	A3	19991111		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9738971	A1	19980220	AU 1997-38971	19970729
EP 934274	A1	19990811	EP 1997-936259	19970729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1239474	A	19991222	CN 1997-198258	19970729
BR 9710637	A	20001031	BR 1997-10637	19970729
JP 2001512416	T2	20010821	JP 1998-509068	19970729
NO 9900399	A	19990329	NO 1999-399	19990128
KR 2000029723	A	20000525	KR 1999-7000826	19990130
PRIORITY APPLN. INFO.:			US 1996-690111 A	19960731
			WO 1997-US13248 W	19970729
OTHER SOURCE(S):		MARPAT 128:167354		
GI				



AB The title compds. [I (A = (un)substituted C₆-10 aryl; D = up to 8 carbon atoms alkyl which is substituted by hydroxy; E, L = (un)substituted up to 8 carbon atoms alkyl; L = (un)substituted C₆-10 aryl; T = R₇X, R₈C(R₉)(R₁₀); R₇, R₈ = cycloalkyl, aryl, etc.; R₉, R₁₀ = H, halo, N₃, etc.), II (R₁ = cycloalkyl, aryl, etc.; E, D = alkyl (up to 8 carbon atoms); E = a bond; V = O, S, NH, etc.), III (R_{1a}, R_{1b} = CF₃, C₁-10 alkyl, C₁-10 alkenyl, etc.; R₂ = C₁-10 alkyl, C₁-10 alkenyl, etc.; R₃ = OH, CF₃, C₁-6 alkanoyl, etc.; Ar = (un)substituted heteroaryl, aryl), IV], useful for the inhibition of cholesterol ester transfer proteins (CETP) (I), for the treatment of hyperlipoproteinemia (II), and for inhibition of the glucagon receptor, leading to treatment of glucagon-mediated conditions such as diabetes (III-IV), were prepd. Thus, redn. of Et 2,6-diisopropyl-4-(4-fluorophenyl)-3-[(4-fluorophenyl)-

chloromethyl]pyridine-5-carboxylate (prepn. described) with LiAlH₄ in THF afforded 69% I [A = 4-FC₆H₄; D = CH₂OH; E = L = iPr; T = 4-FC₆H₄CH₂]. For example, compd. I [A = 4-FC₆H₄; D = CH₂OH; E = L = iPr; T = 4-FC₆H₄CH(NH₂)] showed IC₅₀ of 0.6 .mu.M against CETP.


IT 124863-89-4P 202850-49-5P 202850-67-7P
202850-68-8P 202850-78-0P 202850-80-4P
202850-90-6P 202851-01-2P 202851-03-4P
202851-12-5P 202851-14-7P 202851-17-0P
202851-18-1P 202851-20-5P 202851-21-6P
202851-27-2P 202851-28-3P 202851-29-4P
202851-30-7P 202851-31-8P 202851-32-9P
202851-33-0P 202851-34-1P 202851-35-2P
202851-36-3P 202851-37-4P 202851-38-5P
202851-39-6P 202851-41-0P 202851-42-1P
202851-44-3P 202851-45-4P 202851-46-5P
202851-47-6P 202851-48-7P 202851-49-8P
202851-50-1P 202851-51-2P 202851-52-3P
202851-53-4P 202851-54-5P 202851-55-6P
202851-56-7P 202851-57-8P 202851-58-9P
202851-59-0P 202851-60-3P 202851-61-4P
202851-62-5P 202851-63-6P 202851-64-7P
202851-65-8P 202851-66-9P 202851-67-0P
202851-68-1P 202851-69-2P 202851-70-5P
202851-71-6P 202851-73-8P 202851-74-9P
202851-75-0P 202851-76-1P 202851-77-2P
202851-78-3P 202851-79-4P 202851-80-7P
202851-81-8P 202851-82-9P 202851-83-0P
202851-84-1P 202851-85-2P 202851-86-3P
202851-87-4P 202851-88-5P 202851-89-6P
202851-90-9P 202851-91-0P 202851-92-1P
202851-93-2P 202851-94-3P 202851-95-4P
202851-96-5P 202851-97-6P 202851-98-7P
202851-99-8P 202852-00-4P 202852-01-5P
202852-02-6P 202852-03-7P 202852-04-8P
202852-05-9P 202852-06-0P 202852-07-1P
202852-08-2P 202852-09-3P 202852-10-6P
202852-11-7P 202852-12-8P 202852-13-9P
202852-14-0P 202852-15-1P 202852-16-2P
202852-17-3P 202852-18-4P 202852-19-5P
202852-21-9P 202852-22-0P 202852-23-1P
202852-24-2P 202852-25-3P 202852-26-4P
202852-27-5P 202852-28-6P 202852-29-7P
202852-30-0P 202852-31-1P 202852-32-2P
202852-33-3P 202852-34-4P 202852-35-5P
202852-36-6P 202852-37-7P 202852-38-8P
202852-40-2P 202852-41-3P 202852-42-4P
202852-43-5P 202852-44-6P 202852-45-7P
202852-46-8P 202852-47-9P 202852-48-0P
202852-49-1P 202852-50-4P 202852-51-5P
202852-52-6P 202852-53-7P 202852-54-8P
202852-55-9P 202852-56-0P 202852-58-2P
202852-59-3P 202852-60-6P 202852-61-7P
202852-62-8P 202852-63-9P 202852-64-0P
202852-65-1P 202852-66-2P 202852-67-3P
202852-68-4P 202852-69-5P 202852-70-8P
202852-71-9P 202852-72-0P 202852-73-1P
202852-74-2P 202852-75-3P 202852-76-4P
202852-77-5P 202852-78-6P 202852-79-7P
202852-80-0P 202852-81-1P 202852-82-2P
202852-83-3P 202852-84-4P 202852-85-5P
202852-86-6P 202852-87-7P 202852-88-8P
202852-89-9P 202852-90-2P 202852-91-3P
202852-92-4P 202852-93-5P 202852-94-6P

202852-95-7P 202852-96-8P 202852-97-9P
 202852-98-0P 202852-99-1P 202853-00-7P
 202853-01-8P 202853-02-9P 202853-03-0P
 202853-04-1P 202853-05-2P 202853-06-3P
 202853-07-4P 202853-08-5P 202853-09-6P
 202853-10-9P 202853-11-0P 202853-12-1P
 202853-13-2P 202853-14-3P 202853-16-5P
 202853-17-6P 202853-18-7P 202853-19-8P
 202853-20-1P 202853-21-2P 202853-22-3P
 202853-23-4P 202853-24-5P 202862-11-1P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted pyridines and biphenyls as anti-hypercholesteremic, anti-hyperlipoproteinemic and anti-hyperglycemic agents)


RN 124863-89-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202850-49-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2-ethyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202850-67-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[(4-fluorophenyl)methyl]amino]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202850-68-8 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 202850-78-0 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[1-[4-(trifluoromethyl)phenyl]ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202850-80-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[1-[3-(trifluoromethyl)phenyl]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202850-90-6 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[1-(1-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-01-2 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[1-[4-(trifluoromethyl)phenyl]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-03-4 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[1-[3-(trifluoromethyl)phenyl]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-12-5 CAPLUS


CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[(2-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-14-7 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[(1-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202851-17-0 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-18-1 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-20-5 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-21-6 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-27-2 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethoxy)phenyl]methoxy]methyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202851-28-3 CAPLUS
 CN 3-Pyridinemethanol, 2,4,6-tris(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-29-4 CAPLUS
 CN Benzonitrile, 2-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-30-7 CAPLUS
 CN Benzonitrile, 3-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-31-8 CAPLUS
 CN Benzonitrile, 4-[[[4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-32-9 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclopropyl-4-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-33-0 CAPLUS
 CN 3-Pyridinemethanol, 2-ethyl-4-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-34-1 CAPLUS
 CN 3-Pyridinemethanol, 2-ethyl-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-35-2 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-2-(1-methylethyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 202851-36-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclohexyl-4-(4-fluorophenyl)-2-(1-methylethyl)-5-
 [[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-37-4 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclohexyl-4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202851-38-5 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202851-39-6 CAPLUS
 CN 3-Pyridinemethanol, 6-(4-chlorophenyl)-4-(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-41-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-[2-(4-fluorophenyl)ethyl]-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-42-1 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(trifluoromethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202851-44-3 CAPLUS


CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 202851-45-4 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2-(2,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)


INDEX NAME)




RN 202851-46-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2-(2,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[4-(trifluoromethyl)phenyl]methoxy]methyl- (9CI) (CA INDEX NAME)



RN 202851-47-6 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(trifluoromethyl)phenyl]methoxy]methyl-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-48-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-49-8 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[2-(2-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-(9CI) (CA INDEX NAME)




RN 202851-50-1 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-(2-benzothiazolyl)phenyl]methoxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-(9CI) (CA INDEX NAME)




RN 202851-51-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[4-(trifluoromethoxy)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-52-3 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(2-naphthalenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-53-4 CAPLUS


CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[4-[(4-methylphenyl)sulfonyl]phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-54-5 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[4-(4-fluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202851-55-6 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(4-chlorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-56-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[3-(4-methoxyphenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-57-8 CAPLUS

CN 3-Pyridinemethanol, 5-[[(3,4-difluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-58-9 CAPLUS

CN 3-Pyridinemethanol, 5-[[(2,4-difluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-59-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[(2-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-60-3 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[(3-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-61-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[4-methylphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-62-5 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[1-(4-fluorophenyl)ethoxy)methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-63-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methoxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-64-7 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[4-(1-methylethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-65-8 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[2,4,6-tris(1-methylethyl)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-66-9 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[3-methyl-5-phenoxyphenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-67-0 CAPLUS

CN 3-Pyridinemethanol, 5-[[[2,4-dichlorophenyl]methoxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-68-1 CAPLUS


CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-69-2 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-70-5 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202851-71-6 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(4-fluorophenyl)methoxy]methyl]-6-methyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-73-8 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopropyl-4-(4-fluorophenyl)-2-methyl-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-74-9 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-75-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-76-1 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[3-(3-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-77-2 CAPLUS


CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[2-(2-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-78-3 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[4-(2-benzothiazolyl)phenyl]methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-79-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-5-[(2-naphthalenylmethoxy)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 202851-80-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-phenyl-5-[[[4-(trifluoromethoxy)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-81-8 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-[(4-methylphenyl)sulfonyl]phenyl]methoxy]methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN	202851-82-9	CAPLUS	
CN	3-Pyridinemethanol, 4,6-bis(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)		




RN 202851-83-0 CAPLUS
CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-84-1 CAPLUS
CN 3-Pyridinemethanol, 5-[[4-chlorophenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-85-2 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-(1-methylethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-86-3 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[3-(2-fluorophenoxy)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202851-87-4 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[3-(4-fluorophenoxy)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-88-5 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[3,4-difluorophenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-89-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[(2,4-difluorophenyl)methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-90-9 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[(2-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-91-0 CAPLUS


CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[(3-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-92-1 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-methylphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202851-93-2 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[4-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202851-94-3 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[(2,4-dichlorophenyl)methoxy)methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-95-4 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-96-5 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202851-97-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[2-chloro-4-(trifluoromethyl)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-98-7 CAPLUS


CN 3-Pyridinemethanol, 5-[[[3-([1,1'-biphenyl]-4-yloxy)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202851-99-8 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[2-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202852-00-4 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[3-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-01-5 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-methyl-5-phenoxyphenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-02-6 CAPLUS

CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(1-methylethyl)-5-[(4-phenoxathiinylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-03-7 CAPLUS

CN 3-Pyridinemethanol, 5-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-04-8 CAPLUS


CN 3-Pyridinemethanol, 2-(2-fluorophenyl)-4-(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-05-9 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 202852-06-0 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-07-1 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-08-2 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-09-3 CAPLUS


CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[3-(3-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-10-6 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202852-11-7 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-5-[[3,4-difluorophenyl]methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-12-8 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-5-[[4-(4-chlorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-13-9 CAPLUS

CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[(2-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-14-0 CAPLUS

CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[(4-methylphenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-15-1 CAPLUS


CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-16-2 CAPLUS

CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-5-[[(2,4-dichlorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI)


(CA INDEX NAME)



RN 202852-17-3 CAPLUS
 CN 3-Pyridinemethanol, 6-(4-fluorophenyl)-5-[[4-(2,4-dichlorophenyl)methoxy]methyl]-
 4-[4-fluoro-2-(phenylmethoxy)phenyl]-2-(1-methylethyl)- (9CI) (CA INDEX
 NAME)





RN 202852-18-4 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(2,4-dichlorophenyl)methoxy]methyl]-
 4-[4-fluoro-2-(phenylmethoxy)phenyl]-6-(1-methylethyl)- (9CI) (CA INDEX
 NAME)




RN 202852-19-5 CAPLUS

CN 3-Pyridinemethanol, 4-[4-fluoro-2-[(2-fluorophenyl)methoxy]phenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-21-9 CAPLUS



CN 3-Pyridinemethanol, 4-[4-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-22-0 CAPLUS
 CN 3-Pyridinemethanol, 4-[2-[(4-chlorophenyl)methoxy]-4-fluorophenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-23-1 CAPLUS
 CN 3-Pyridinemethanol, 4-[4-fluoro-3-[(2-fluorophenyl)methoxy]phenyl]-5-[[4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-24-2 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 202852-25-3 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[(3,4-difluorophenyl)methoxy]methyl]-2,4-bis(4-fluorophenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 202852-26-4 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-methyl-5-[[[3-(trifluoromethyl)phenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-27-5 CAPLUS
 CN 3-Pyridinemethanol, 2-(3-chlorophenyl)-5-[[[(3,4-difluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-6-(1-methylethyl)- (9CI)
 (CA INDEX NAME)




RN 202852-28-6 CAPLUS
 CN 3-Pyridinemethanol, 2-(3-chlorophenyl)-4-(4-fluorophenyl)-5-[[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-29-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-[2-(4-fluorophenyl)ethyl]-5-[[4-fluorophenyl)methoxy]methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-30-0 CAPLUS
 CN 3-Pyridinemethanol, 5-[[3,4-difluorophenyl)methoxy]methyl]-4-(4-fluorophenyl)-6-[2-(4-fluorophenyl)ethyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-31-1 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-
 2-[(4-fluorophenyl)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-32-2 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-
 6-[(4-fluorophenyl)methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-33-3 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-
 4-(4-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-34-4 CAPLUS
CN 3-Pyridinemethanol, 4-(4-chlorophenyl)-2-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN	202852-35-5	CAPLUS	
CN	3-Pyridinemethanol, 4-(4-chlorophenyl)-2-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)		




RN 202852-36-6 CAPLUS
CN 3-Pyridinemethanol, 4-(3-chlorophenyl)-2-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN	202852-37-7	CAPLUS	
CN	3-Pyridinemethanol, 4-(3-chlorophenyl)-2-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)		




RN 202852-38-8 CAPLUS
 CN 3-Pyridinemethanol, 6-(1-ethylpropyl)-2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)



RN 202852-40-2 CAPLUS
 CN 3-Pyridinemethanol, 6-(1-ethylpropyl)-2,4-bis(4-fluorophenyl)-5-[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-41-3 CAPLUS
 CN 3-Pyridinemethanol, 4-(3,4-dichlorophenyl)-2-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-42-4 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202852-43-5 CAPLUS


CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-6-(1-methylethyl)-4-(3-methylphenyl)-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-44-6 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-45-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(3,5-dichlorophenyl)-2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-46-8 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-4-(3-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-47-9 CAPLUS

CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-4-(2-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-48-0 CAPLUS


CN 3-Pyridinemethanol, 4-(2,3-dichlorophenyl)-2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-49-1 CAPLUS
 CN 3-Pyridinemethanol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI)
 (CA INDEX NAME)




RN 202852-50-4 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-4-[4-fluoro-3-(trifluoromethyl)phenyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-51-5 CAPLUS
 CN 3-Pyridinemethanol, 4-[3-chloro-4-(trifluoromethyl)phenyl]-2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI)
 (CA INDEX NAME)




RN 202852-52-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-53-7 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-6-cyclopentyl-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-54-8 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-55-9 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-5-[[[(2,4-dichlorophenyl)methoxy]methyl]-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-56-0 CAPLUS
CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]methyl]-6-cyclopentyl-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-58-2 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopropyl-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-59-3 CAPLUS
CN 3-Pyridinemethanol, 6-cyclopropyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-60-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopropyl-5-[[(2,4-dichlorophenyl)methoxy]methyl]-
 2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-61-7 CAPLUS
 CN 3-Pyridinemethanol, 2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-
 6-(1-methylethyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202852-62-8 CAPLUS
 CN 3-Pyridinemethanol, 2,4,6-tris(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-63-9 CAPLUS
 CN 3-Pyridinemethanol, 4-(2,3-dichlorophenyl)-2,6-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-64-0 CAPLUS
 CN 3-Pyridinemethanol, 4-(2-chlorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202852-65-1 CAPLUS
 CN 3-Pyridinemethanol, 4-(2-chlorophenyl)-2,6-bis(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-66-2 CAPLUS
 CN 3-Pyridinemethanol, 4-(2,4-dichlorophenyl)-2-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-67-3 CAPLUS

CN 3-Pyridinemethanol, 4-(2,4-dichlorophenyl)-2,6-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-68-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-[3-(trifluoromethyl)phenyl]-5-[[3-(trifluoromethyl)phenyl]methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202852-69-5 CAPLUS


CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-6-(1-methylethyl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 202852-70-8 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(fluorophenyl)methoxy]methyl]-
 6-(1-methylethyl)-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-71-9 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-(3-
 methylphenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA
 INDEX NAME)




RN 202852-72-0 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]-6-(1-methylethyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 202852-73-1 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-(4-methylphenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-74-2 CAPLUS


CN 3-Pyridinemethanol, 2-(2-chlorophenyl)-4-(4-fluorophenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-75-3 CAPLUS
 CN 3-Pyridinemethanol, 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-[[4-(fluorophenyl)methoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-76-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-(4-methoxyphenyl)-6-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-77-5 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[[4-(4-fluorophenyl)methoxy]methyl]-2-(4-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-78-6 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-(2-methoxyphenyl)-6-(1-methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-79-7 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[(4-fluorophenyl)methoxy]methyl]-
 2-(2-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-80-0 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2-(3-methoxyphenyl)-6-(1-
 methylethyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA
 INDEX NAME)




RN 202852-81-1 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-2-(3-methoxyphenyl)-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202852-82-2 CAPLUS


CN 3-Pyridinemethanol, 2-cyclohexyl-4,6-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-83-3 CAPLUS
 CN 3-Pyridinemethanol, 2-cyclohexyl-4,6-bis(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202852-84-4 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclohexyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-85-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclohexyl-2,4-bis(4-fluorophenyl)-5-[[[4-fluorophenyl)methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-86-6 CAPLUS

CN 3-Pyridinemethanol, 5-[[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]methyl]-6-cyclohexyl-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-87-7 CAPLUS

CN 3-Pyridinemethanol, 6-cyclohexyl-5-[[[2,4-dichlorophenyl]methoxy]methyl]-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202852-88-8 CAPLUS


CN 3-Pyridinemethanol, 2-(4-chlorophenyl)-6-cyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-89-9 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[3-(trifluoromethyl)phenyl]-5-[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-90-2 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-5-[[4-fluorophenyl]methoxy]methyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 202852-91-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclobutyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-92-4 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclobutyl-2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-93-5 CAPLUS
 CN 3-Pyridinemethanol, 2-cycloheptyl-4,6-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-94-6 CAPLUS
 CN 3-Pyridinemethanol, 2-cycloheptyl-4,6-bis(4-fluorophenyl)-5-[[[4-fluorophenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202852-95-7 CAPLUS
 CN 3-Pyridinemethanol, 6-cycloheptyl-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN	202852-96-8	CAPLUS
CN	3-Pyridinemethanol, 6-cycloheptyl-2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)	




RN	202852-97-9	CAPLUS
CN	3-Pyridinemethanol, 4,6-bis(4-fluorophenyl)-2-(2-furanyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)	




RN	202852-98-0	CAPLUS
CN	3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-6-(2-furanyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)	




RN 202852-99-1 CAPLUS
 CN 3-Pyridinemethanol, 6-(cyclopentylmethyl)-2,4-bis(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202853-00-7 CAPLUS
 CN 3-Pyridinemethanol, 6-(cyclopentylmethyl)-2,4-bis(4-fluorophenyl)-5-[[3-(trifluoromethyl)phenyl)methoxy)methyl]- (9CI) (CA INDEX NAME)




RN 202853-01-8 CAPLUS
 CN 3-Pyridinemethanol, 5-[[[3,5-bis(trifluoromethyl)phenyl)methoxy)methyl]-6-(cyclopentylmethyl)-2,4-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 202853-02-9 CAPLUS
 CN 3-Pyridinemethanol, 6-(cyclohexylmethyl)-2,4-bis(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202853-03-0 CAPLUS
 CN 3-Pyridinemethanol, 6-(cyclohexylmethyl)-2,4-bis(4-fluorophenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-04-1 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[4-(trifluoromethyl)phenyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-05-2 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[4-(trifluoromethyl)phenyl]methoxy]methyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-(9CI) (CA INDEX NAME)




RN 202853-06-3 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(1-naphthalenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]-(9CI) (CA INDEX NAME)





RN 202853-07-4 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(1-naphthalenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-(9CI) (CA INDEX NAME)




RN 202853-08-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(2-naphthalenyl)-5-
 [[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-09-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(2-naphthalenyl)-5-
 [[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-10-9 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(3-methylphenyl)-5-
[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)

RN 202853-11-0 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-(3-methylphenyl)-5-
[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)

RN 202853-12-1 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-
(9CI) (CA INDEX NAME)

RN 202853-13-2 CAPLUS


CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]-
(9CI) (CA INDEX NAME)




RN 202853-14-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI)
 (CA INDEX NAME)



RN 202853-16-5 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI)
 (CA INDEX NAME)




RN 202853-17-6 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-18-7 CAPLUS

CN 3-Pyridinemethanol, 6-cyclopentyl-2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-19-8 CAPLUS

CN 3-Pyridinemethanol, 2,6-dicyclopentyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-20-1 CAPLUS


CN 3-Pyridinemethanol, 2,6-dicyclopentyl-4-(4-fluorophenyl)-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-21-2 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-22-3 CAPLUS
 CN 3-Pyridinemethanol, 6-cyclopentyl-4-(4-fluorophenyl)-2-[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202853-23-4 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis[2-[3-(trifluoromethyl)phenyl]ethyl]-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202853-24-5 CAPLUS
 CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis[2-[3-(trifluoromethyl)phenyl]ethoxy]methyl-5-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202862-11-1 CAPLUS
 CN 3-Pyridinemethanol, 2,4-bis(4-fluorophenyl)-5-[[[1-(4-fluorophenyl)ethoxy]methyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 202857-35-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of substituted pyridines and biphenyls as anti-hypercholesteremic, anti-hyperlipoproteinemic and anti-hyperglycemic agents)
 RN 202857-35-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-cyclopentyl-2-ethyl-4-(4-fluorophenyl)-5-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:116189 CAPLUS

DOCUMENT NUMBER: 128:140621

TITLE: Preparation of tetrahydroquinolines and analogs as cholesteryl ester transfer protein inhibitors

INVENTOR(S):

Schmidt, Gunter; Brandes, Arndt; Angerbauer, Rolf; Logers, Michael; Muller-Gliemann, Matthias; Schmeck, Carsten; Bremm, Klaus-Dieter; Bischoff, Hilmar; Schmidt, Delf; Schuhmacher, Joachim; Giera, Henry; Paulsen, Holger; Naab, Paul; Conrad, Michael; Stoltefuss, Jurgen

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Eur. Pat. Appl., 173 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

German



FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 818448	A1	19980114	EP 1997-110275	19970624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19627419	A1	19980115	DE 1996-19627419	19960708
DE 19707199	A1	19980827	DE 1997-19707199	19970224
PRIORITY APPLN. INFO.:			DE 1996-19627419 A	19960708
			DE 1997-19707199 A	19970224

OTHER SOURCE(S):
GI

MARPAT 128:140621





AB Title compds. [I; A = (un)substituted aryl; D = (un)substituted aryl(alkyl), etc.; E = (cyclo)alkyl, (un)substituted Ph, etc.; R1R2 = substituted alkylene] were prepd. Thus, 1,3-cyclohexanedione was cyclocondensed with 4-FC6H4CHO and Me2CHCH(NH2):CHCO2Me and the product converted in 8 steps to title compd. II. Data for biol. activity of I were given.

IT 202203-35-8P 202203-36-9P 202203-37-0P
202203-44-9P 202203-45-0P 202203-46-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydroquinolines and analogs as cholesteryl ester transfer protein inhibitors)



RN 202203-35-8 CAPLUS

CN 5-Quinolinol, 2,4-bis(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)





RN 202203-36-9 CAPLUS


CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-37-0 CAPLUS
 CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-44-9 CAPLUS
 CN 5-Quinolinol, 4-(4-fluorophenyl)-3-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]-5,6,7,8-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202203-45-0 CAPLUS
 CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202203-46-1 CAPLUS
 CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
 [[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)





L8 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1998:55678 CAPLUS
 DOCUMENT NUMBER: 128:140619
 TITLE: Preparation of tetrahydroquinolines and analogs as
 cholesteryl ester transfer protein inhibitors
 INVENTOR(S): Schmidt, Gunter; Brandes, Arndt; Angerbauer, Rolf;
 Loegers, Michael; Mueller-Gliemann, Matthias; Schmeck,
 Carsten; Bremm, Klaus-Dieter; Bischoff, Hilmar;
 Schmidt, Delf; Schuhmacher, Joachim
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 128 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19627419	A1	19980115	DE 1996-19627419	19960708
EP 818448	A1	19980114	EP 1997-110275	19970624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 10067746	A2	19980310	JP 1997-190736	19970702
AU 9728451	A1	19980115	AU 1997-28451	19970703
AU 728136	B2	20010104		
CA 2209640	AA	19980108	CA 1997-2209640	19970704
NO 9703145	A	19980109	NO 1997-3145	19970707
CN 1175574	A	19980311	CN 1997-114557	19970708

BR 9703884 A 19980901 BR 1997-3884 19970708
 US 6069148 A 20000530 US 1997-889530 19970708
 US 6207671 B1 20010327 US 2000-521648 20000308
 PRIORITY APPLN. INFO.: DE 1996-19627419 A 19960708
 DE 1997-19707199 A 19970224
 US 1997-889530 A2 19970708



OTHER SOURCE(S): MARPAT 128:140619
 GI





AB Title compds. [I; A = (un)substituted aryl; D = (un)substituted aryl(alkyl), etc.; E = (cyclo)alkyl, (un)substituted Ph, etc.; R1R2 = substituted alkylene] were prepd. Thus, 1,3-cyclohexanedione was cyclocondensed with 4-FC6H4CHO and Me2CHCH(NH2):CHCO2Me and the product converted in 8 steps to title compd. II. Data for biol. activity of I were given.

IT 202203-35-8P 202203-36-9P 202203-37-0P
 202203-44-9P 202203-45-0P 202203-46-1P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tetrahydroquinolines and analogs as cholesteryl ester transfer protein inhibitors)


RN 202203-35-8 CAPLUS
 CN 5-Quinolinol, 2,4-bis(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-36-9 CAPLUS
CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-37-0 CAPLUS
CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-44-9 CAPLUS
 CN 5-Quinolinol, 4-(4-fluorophenyl)-3-[[4-(4-fluorophenyl)methoxy]methyl]-
 5,6,7,8-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 202203-45-0 CAPLUS
 CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
 [[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202203-46-1 CAPLUS
 CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
 [[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1997:706935 CAPLUS
 DOCUMENT NUMBER: 128:3591
 TITLE: Potent NK1 receptor antagonists: synthesis and antagonistic activity of various heterocycles with an N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl substituent
 AUTHOR(S): Ikeura, Yoshinori; Tanaka, Toshimasa; Kiyota, Yutaka; Morimoto, Shinji; Ogino, Masaki; Ishimaru, Takenori; Kamo, Izumi; Doi, Takayuki; Natsugari, Hideaki
 CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532, Japan
 SOURCE: Chem. Pharm. Bull. (1997), 45(10), 1642-1652
 PUBLISHER: CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Pharmaceutical Society of Japan
 LANGUAGE: Journal
 GI English



I

AB Various N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl heterocycles modified at rings A and B in the isoquinolone and pyrido[3,4-b]pyridine nuclei were prepd. and evaluated for NK1 receptor antagonistic activities. The structure-activity relationship studies on this series, along with conformational anal., showed that for ring A, 6-membered heterocycles are preferable to 5-membered heterocycles (a ca. 300-fold difference in potency), the 6-membered ring seems to function as an anchor by fixing the pendant Ph group in a desirable orientation for receptor binding, and since compds. with arom. rings and those with aliph. rings as ring B both show good potency, this ring does not seem to be essential for receptor recognition. Among the compds. synthesized, the tetrahydropyridine


derivs. I [RR1 = NMe(CH2)3, CH2NMeCH2CH2, (CH2)3NMe] exhibited excellent inhibitory effects both in vitro and in vivo, with potent activity upon oral administration (ED50-0.20-0.27 mg/kg) (capsaicin-induced plasma extravasation in guinea pig trachea).

IT **198878-48-7P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoylpyridinone analogs as potent NK1 receptor antagonists)

RN 198878-48-7 CAPLUS

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:728630 CAPLUS

DOCUMENT NUMBER: 126:8145

TITLE: Preparation of polycyclic heterocycles as tachykinin receptor antagonists

INVENTOR(S):

Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki; Ikeura, Yoshinori; Kimura, Chiharu

PATENT ASSIGNEE(S):

Takeda Chemical Industries, Ltd., Japan

SOURCE:

Eur. Pat. Appl., 94 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733632	A1	19960925	EP 1996-104500	19960321
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
NO 9601160	A	19960925	NO 1996-1160	19960321
TW 394773	B	20000621	TW 1996-85103427	19960321
CA 2172421	AA	19960925	CA 1996-2172421	19960322
AU 9648261	A1	19961003	AU 1996-48261	19960322
AU 699611	B2	19981210		
CN 1140172	A	19970115	CN 1996-106081	19960323
IL 117631	A1	20001121	IL 1996-117631	19960324
BR 9601125	A	19980106	BR 1996-1125	19960325
PRIORITY APPLN. INFO.:			JP 1995-91436	A 19950324
			JP 1995-207553	A 19950720
			JP 1995-264727	A 19950918
			JP 1996-30033	A 19960123

OTHER SOURCE(S): MARPAT 126:8145

GI For diagram(s), see printed CA Issue.

AB Title compds. [I; R = (CH2)nR4; R1,R2 = H or a substituent; R1R2 = atoms



to complete a (hetero)cyclic ring; ring B = heterocyclic ring; R3,R4 = (hetero)cyclic ring; X-Y = N:C, C(O)N, C(S)N; n = 1-6] were prepd. Thus, 4-BrC6H4Me was condensed with 2,3-pyridinedicarboxylic acid and the product amidated by HN(CH2CN)2 to give, after cyclization in 5 addnl. steps, 7-[3,5-bis(trifluoromethyl)benzyl]-6,7,8,9-tetrahydro-5-(4-methylphenyl)-6,11-dioxo-11H-pyrazino[2,1-g][1,7]naphthyridine. Data for in vitro biol. activity of selected I were given.

IT 183550-95-0P 183551-05-5P 183551-08-8P
 183551-09-9P 183551-11-3P 183551-12-4P
 183551-16-8P 183551-20-4P 183551-21-5P
 183551-25-9P 183551-26-0P 183551-27-1P
 183551-28-2P 183551-29-3P 183551-30-6P
 183551-31-7P 183551-32-8P 183551-33-9P
 183551-34-0P 183551-35-1P 183551-36-2P
 183551-37-3P 183551-47-5P 183551-48-6P
 183551-49-7P 183551-50-0P 183551-56-6P
 183551-58-8P 183551-59-9P 183551-61-3P
 183551-67-9P 183551-68-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of polycyclic heterocycles as tachykinin receptor antagonists)


RN 183550-95-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-05-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-aminoethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-08-8 CAPLUS



CN Carbamic acid, [2-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(2-chloro-4-phenyl-3-pyridinyl)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 183551-09-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(3-hydroxypropyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-11-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-12-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(3-hydroxypropyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-16-8 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-20-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-21-5 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-25-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-26-0 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[2-(2-hydroxyethyl)(phenylmethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-27-1 CAPLUS

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(3-hydroxypropyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-28-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](3-hydroxypropyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-29-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 183551-30-6 CAPLUS


CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dichlorophenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-31-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-32-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 183551-33-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-chloro-N-(3-hydroxypropyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 183551-34-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-35-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-36-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-37-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-47-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-48-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183551-49-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-50-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-56-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-58-8 CAPLUS



CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.




RN 183551-59-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-61-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-67-9 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl-N3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-68-0 CAPLUS
 CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N2-ethyl-N3-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:835514 CAPLUS
 DOCUMENT NUMBER: 123:256684
 TITLE: Preparation of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compounds as tachykinin antagonists and inhibitors of plasma extravasation.
 INVENTOR(S): Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 72 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 652218	A1	19950510	EP 1994-117576	19941108
EP 652218	B1	20010711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
NO 9404252	A	19950511	NO 1994-4252	19941108
AT 203024	E	20010715	AT 1994-117576	19941108
CA 2135440	AA	19950511	CA 1994-2135440	19941109

FI 9405281	A	19950511	FI 1994-5281	19941109
AU 9477738	A1	19950518	AU 1994-77738	19941109
AU 678295	B2	19970522		
BR 9404403	A	19950718	BR 1994-4403	19941109
JP 08067678	A2	19960312	JP 1994-274699	19941109
RU 2135471	C1	19990827	RU 1994-40174	19941109
HU 68810	A2	19950519	HU 1994-3230	19941110
CN 1107476	A	19950830	CN 1994-113866	19941110
CN 1052004	B	20000503		
US 5585385	A	19961217	US 1994-338762	19941110
BR 9501976	A	19960430	BR 1995-1976	19950509

PRIORITY APPLN. INFO.:

JP 1993-281178	A	19931110
JP 1993-337488	A	19931228
JP 1994-33637	A	19940303
JP 1994-138551	A	19940621

OTHER SOURCE(S): MARPAT 123:256684

GI For diagram(s), see printed CA Issue.


AB Title compds. [I; ring A, ring B = (substituted) homo- or heterocyclyl, .gtoreq.1 of them = (substituted) heterocyclyl; ring C = (substituted) benzene ring; R = H, (substituted) hydrocarbyl; 1 of X, Y = NR1, O; the other = CO, CS; or 1 of them = N; and the other = :CR2; R1 = H, (substituted) hydrocarbyl; R2 = H, halo, (substituted) hydrocarbyl, amino, OH; n = 1, 2], were prepd. Thus, 5-(4-fluorophenyl)-7,8-dihydro-7-methyl-8-oxo-6-pyrido[3,4-b]pyridinecarboxylic acid (prepn. given) was refluxed with SOCl2 in benzene and ther residue in THF was refluxed with N-[3,5-bis(trifluoromethyl)benzyl]methylamine and Et3N to give N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-fluorophenyl)-7,8-dihydro-N,7-di methyl-8-oxo-6-pyrido[3,4-b]pyridinecarboxamide (II). II inhibited substance P binding to IM-9 human lymphoblasts with IC50 = 0.08 nM. Tablets contg. II were prepd.

IT 168541-24-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compds. as tachykinin antagonists and inhibitors of plasma extravasation)

RN 168541-24-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:229214 CAPLUS

DOCUMENT NUMBER: 122:10041

TITLE:

Preparation of heterocyclic-substituted alkyl amide
ACAT inhibitors

INVENTOR(S):

Lee, Helen Tsenwhei; Picard, Joseph Armand; O'Brien, Patrick Michael; Purchase, Claude Forsey, Jr.; Roth, Bruce David; Sliskovic, Drago Robert; White, Andrew

PATENT ASSIGNEE(S): David
 SOURCE: Warner-Lambert Co., USA
 PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419330	A1	19940901	WO 1994-US1420	19940208
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5366987	A	19941122	US 1993-19411	19930218
AU 9461358	A1	19940914	AU 1994-61358	19940208
AU 679726	B2	19970710		
EP 684945	A1	19951206	EP 1994-908008	19940208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08507060	T2	19960730	JP 1994-519020	19940208
PRIORITY APPLN. INFO.:			US 1993-19411	A 19930218
			US 1991-748568	B2 19910822
			US 1992-913643	B2 19920720
			WO 1994-US1420	W 19940208

OTHER SOURCE(S): MARPAT 122:10041


AB Title compds. R1NHCO(CH2)nCR2R3XR4 (I; n = 0-2; R1 = (substituted) Ph, (substituted) naphthyl, substituted pyrazolyl, 6,7-dimethyl-1,8-naphthyridinyl, substituted quinolinyl, C1-18 hydrocarbyl, C3-8 cycloalkyl, substituted heterocyclyl; R2, R3 = H, halo, HO, C1-12 alkyl, C3-8 cycloalkyl, Ph, phenyl-C1-4 alkyl, C2-6 alkenyl or R2R3C = C1-4 alkylidene, benzylidene, C3-7 spiroalkyl, (substituted) naphthyl; X = (substituted) 5-membered heterocyclyl; R4 = (substituted) C1-20 hydrocarbyl, C1-20 alkoxy, C1-20 alkylthio. (substituted) Ph) or a salt, or enantiomer thereof, useful as ACAT (acyl-Co-A:cholesterol acyltransferase) inhibitors are prepd. NCCH2CO2Et in DMF was treated with NaN3 to give Et 2H-tetrazoleacetate which in 3 steps was converted to I (n = 0, R1 = 2,6-diisopropylphenyl, R2 = R3 = H, R4X = 2-n-dodecyl-2H-tetrazol-5-yl) (II). In an in vitro test, the IC50 of II was 0.003 .mu.M.

IT 148926-65-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of heterocyclic-substituted alkyl amide ACAT inhibitors)

RN 148926-65-2 CAPLUS

CN 2H-Tetrazole-5-acetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2-dodecyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)




L8 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:533979 CAPLUS

Searched by Barb O'Bryen STIC 308-4291

DOCUMENT NUMBER: 121:133979
 TITLE: Substituted pyridines as HMG-CoA reductase inhibitors.
 INVENTOR(S): Angerbauer, Rolf; Fey, Peter; Huebsch, Walter;
 Philipps, Thomas; Bischoff, Hilmar; Krause, Hans
 Peter; Petersen Von Gehr, Joerg; Schmidt, Delf
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Eur. Pat. Appl., 18 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 603699	A1	19940629	EP 1993-120057	19931213
EP 603699	B1	19970115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4244029	A1	19940630	DE 1992-4244029	19921224
AT 147741	E	19970215	AT 1993-120057	19931213
ES 2096843	T3	19970316	ES 1993-120057	19931213
JP 06234740	A2	19940823	JP 1993-343310	19931217
US 5409910	A	19950425	US 1993-169804	19931217
CA 2112011	AA	19940625	CA 1993-2112011	19931221
			DE 1992-4244029	19921224

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 121:133979
 GI




AB Novel substituted pyridines were disclosed and claimed for the treatment of hyperlipoproteinemia. An example compd., 7-[[4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)]-3-pyridinyl]-6-hepten-1,3,5-triol (I) was prepd. I inhibited cholesterol biosynthesis in rat liver (IC₅₀ = 20 .mu.g/kg).

IT **157199-23-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as HMG CoA reductase inhibitor anticholesteremic)

RN 157199-23-0 CAPLUS

CN 6-Heptene-1,3,5-triol, 7-[4-(4-fluorophenyl)-5-[[4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-, [S-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 157199-27-4

RL: RCT (Reactant)


(reactant for [(fluorophenyl)pyridinyl]heptenetriol anticholesteremic)

RN 157199-27-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-[[4-(fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, [S-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● Na

L8 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:257714 CAPLUS

DOCUMENT NUMBER: 122:56051

TITLE: Condensed heterocyclic compounds, their production and use

INVENTOR(S): Natsugari, Hideaki; Ikeda, Hitoshi; Ishimaru, Takenori; Doi, Takayuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 161 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 585913	A2	19940309	EP 1993-114024	19930902
EP 585913	A3	19940525		
EP 585913	B1	19971229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
NO 9303133	A	19940307	NO 1993-3133	19930902
NO 179904	B	19960930		
NO 179904	C	19970108		
US 5482967	A	19960109	US 1993-114841	19930902
AT 161530	E	19980115	AT 1993-114024	19930902
CA 2105518	AA	19940305	CA 1993-2105518	19930903
AU 9346132	A1	19940310	AU 1993-46132	19930903
AU 667739	B2	19960404		
FI 9303857	A	19940517	FI 1993-3857	19930903
JP 07010844	A2	19950113	JP 1993-220333	19930903
HU 67284	A2	19950328	HU 1993-2499	19930903
CN 1090274	A	19940803	CN 1993-118986	19930904
US 5700810	A	19971223	US 1995-540913	19951011
PRIORITY APPLN. INFO.:			JP 1992-237481	19920904
			JP 1993-103328	19930428
			US 1993-114841	19930902

OTHER SOURCE(S): MARPAT 122:56051
GI



I

AB Novel compds. represented by I were prepd.; ring A may be substituted; ring B represents an optionally substituted benzene ring; either X or Y represents -NR₁- (R₁ represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group), -O- or -S-, the other representing -CO-, -CS-, or -C(R₂)R_{2a}- (R₂ and R_{2a} independently represent a hydrogen atom or an optionally substituted hydrocarbon group), or either X or Y represents -N=, the other representing =CR₃- (R₃ represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted amino group, a substituted hydroxyl group or a mercapto group substituted by an optionally substituted hydrocarbon group); ---- represents a single or double bond; when ---- is a single bond, Z represents -CR₄- (R₄ represents a hydrogen atom, hydroxyl group or an optionally substituted hydrocarbon group) or a nitrogen atom, or (ii) when ---- is a double bond, Z represents a carbon atom. D represents a C1-3 alkylene group which may be substituted by an oxo group or a thioxo group, or D and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thioxo group; E represents -NR₅- (R₅ represents a hydrogen atom or an optionally substituted hydrocarbon group), -O- or -S(O)_n- (n is 0, 1 or 2), or R₅ and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thioxo group. G represents a bond or a C1-3 alkylene group. Ar represents an optionally substituted aryl or heterocyclic group. Some representative prepd. compds. were benzopyran-, quinoline-, isoquinoline-


and quinoxalinecarboxamides. I and its salts have an excellent activity of inhibiting ACAT, lowering cholesterol in blood and inhibiting tachykinin receptor (test data given).

IT 159818-59-4P 159818-65-2P 159818-66-3P
159818-67-4P 159818-68-5P 159818-69-6P
159818-70-9P 159818-71-0P 159818-72-1P
159818-73-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of)


RN 159818-59-4 CAPLUS

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-65-2 CAPLUS

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-66-3 CAPLUS

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-67-4 CAPLUS


CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-68-5 CAPLUS
 CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-69-6 CAPLUS
 CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,6,7-trimethoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 159818-70-9 CAPLUS
 CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-71-0 CAPLUS
 CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-72-1 CAPLUS

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylamino)-4-phenyl- (9CI) (CA INDEX NAME)



RN 159818-73-2 CAPLUS

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylthio)-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:298580 CAPLUS

DOCUMENT NUMBER: 120:298580

TITLE: Reactions of 5-(p-anisyl)-2-methyl-7-(p-tolyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one

AUTHOR(S): Madkour, Hassan M. F.; Salem, Mounir A. I.; Abdel-Rahman, Taha M.; Azab, Mohamed E.

CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Abbassia, Egypt


SOURCE: Heterocycles (1994), 38(1), 57-69

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB 5-(P-Anisyl)-2-methyl-7-(p-tolyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one (I, Ar = 4-MeOC₆H₄, Ar1 = 4-MeC₆H₄, throughout) was prepd. The reactivity of I towards nucleophilic reagents was investigated. 5-(P-Anisyl)-2-methyl-7-(p-tolyl)-4H-pyrido[2,3-d]pyrimidin-4-one (II, R = H) was synthesized from I by the action of ammonium acetate and zinc chloride. The structure of II was chem. confirmed by reactions with acetic anhydride, benzoyl chloride, chloroacetic acid, Me iodide, di-Me sulfate and Et bromoacetate. II reacted with secondary and primary amines under Mannich conditions to afford 5-(p-anisyl)-2-methyl-3-methylene substituted amino-7-(p-tolyl)-4H-pyrido[2,3-d]pyrimidin-4-ones II (R = CH₂R₁, R₁ = piperidino, morpholino) and II (R = CH₂NR₂CH₂OH, R₂ = Me, CH₂Ph, Ph), resp. Sulfuration of II (R = H) gave the thione 5-(p-anisyl)-2-methyl-7-(p-tolyl)-4H-pyrido[2,3-d]pyrimidin-4-thione III.

IT 154778-16-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and intramol. cyclocondensation of)

RN 154778-16-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-(acetylamino)-4-(4-methoxyphenyl)-6-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:517255 CAPLUS

DOCUMENT NUMBER: 119:117255

TITLE: Preparation of amide tetrazole ACAT inhibitors

INVENTOR(S): O'Brien, Patrick Michael; Picard, Joseph Armand; Purchase, Claude Forsey, Jr.; Roth, Bruce David; Sliskovic, Drago Robert; White, Andrew David

PATENT ASSIGNEE(S): Warner-Lambert Co., USA


SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304052	A1	19930304	WO 1992-US6388	19920803
W: AU, CA, CS, FI, HU, JP, KR, NO, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
CA 2114017	AA	19930304	CA 1992-2114017	19920803
AU 9224147	A1	19930316	AU 1992-24147	19920803
AU 657790	B2	19950323		
EP 600950	A1	19940615	EP 1992-917230	19920803
EP 600950	B1	19961023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 06510040	T2	19941110	JP 1992-504315	19920803
HU 70754	A2	19951030	HU 1994-491	19920803
CZ 281314	B6	19960814	CZ 1992-361	19920803
AT 144501	E	19961115	AT 1992-917230	19920803
ES 2093270	T3	19961216	ES 1992-917230	19920803
RU 2117664	C1	19980820	RU 1994-16198	19920803
JP 3113678	B2	20001204	JP 1993-504315	19920803
ZA 9206332	A	19940221	ZA 1992-6332	19920821
FI 9400731	A	19940415	FI 1994-731	19940216
NO 9400596	A	19940222	NO 1994-596	19940221
PRIORITY APPLN. INFO.:				
			US 1991-748568	A 19910822
			US 1992-913643	A 19920720
			WO 1992-US6388	A 19920803
OTHER SOURCE(S): MARPAT 119:117255				
GI				




AB Title compds. I ($n = 0-2$; $R^1 =$ (substituted) Ph, -naphthyl, 2,6-dialkoxy-pyrimidin-5-yl, dialkylpypyrzazol-4-yl, 2,4-dimethyl-1,8-naphthyridin-7-yl, etc.; $R^2, R^3 =$ H, halo, HO, C1-12 alkyl, C3-8 cycloalkyl, (substituted) phenylalkyl, C2-6 alkenyl, $R^2R^3C =$ C1-4 alkylidene, benzylidene, C3-7 spiroalkyl, or when $R^2 =$ H, F, C1-12 alkyl, $R^3 =$ 5-6-membered heterocyclyl) or a salt thereof, are prepd. Et tetrazoleacetate (prepn. given) was added to $Br(CH_2)_{11}Me$ Et₃N to give the 1-dodecyl- and 2-dodecyl esters. The 2-dodecyl ester was converted to free acid. To this acid in THF was added carbonyldiimidazole followed by 2,6-(Me₂CH)₂C₆H₃NH₂ to give I [$R^1 =$ 2,6-(Me₂CH)₂C₆H₃, $n = 0$, $R^2 = R^3 =$ H, $R^4 =$ 2-(CH₂)₁₁Me] (II). In vitro test for ACAT (acyl-CoA:cholesterol acyltransferase) inhibition for II was IC₅₀ = 0.003 .mu.M. Addnl. I were prepd. and tested.

IT 148926-65-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as cholesterol acyltransferase inhibitor)


RN 148926-65-2 CAPLUS

CN 2H-Tetrazole-5-acetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2-dodecyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)




L8 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:469733 CAPLUS
 DOCUMENT NUMBER: 117:69733
 TITLE: Tricyclic heterocyclic compounds, their production and use
 INVENTOR(S): Meguro, Kanji; Tawada, Hiroyuki; Ikeda, Hitoshi
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 481243	A1	19920422	EP 1991-116099	19910921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05009179	A2	19930119	JP 1991-202003	19910812
US 5264454	A	19931123	US 1991-765182	19910925
CA 2052287	AA	19920328	CA 1991-2052287	19910926
US 5418239	A	19950523	US 1993-117950	19930908
PRIORITY APPLN. INFO.:			JP 1990-259657	19900927
			JP 1991-202003	19910812
			US 1991-765182	19910925
OTHER SOURCE(S):			MARPAT 117:69733	
GI				



I



II


AB Title compds. I [A = (substituted) Ph; R1 = (substituted) hydrocarbyl; X = (O)mN:CR2, R3NCO; R2 = H, alkyl, alkoxy; R3 = H, alkyl, OCO; Y = bond, HN, C1-2 alkylene, CH:CH; m = 0, 1; n = 3-6] or a salt thereof, inhibitors of ACAT (acyl-CoA:cholesterol acyltransferase), are prepd. Et3N was added to a mixt. of 4-(2-methylphenyl)-2-oxo-2,6,7,8-tetrahydrocyclopenta[g]-1-benzopyran-3-carboxylic acid, diphenylphosphoryl azide and benzene, the mixt. stirred at room temp. for 30 min, then refluxed for 30 min to give the title compd. II. II at 10⁻⁶M inhibited ACAT 99.5%. II at 234 mg/kg/day in rats lowered plasma cholesterol to 78.1 \pm 12.6 mg/dL vs. 181.8 \pm 60.4 for control.

IT 142626-36-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as cholesterol acyltransferase inhibitor)

RN 142626-36-6 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-7,8-dihydro-6H-cyclopenta[g]quinolin-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



L8 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1992:214482 CAPLUS

DOCUMENT NUMBER: 116:214482

TITLE: Thienopyridinyl urea derivatives, a method for their preparation and their use as acyl CoA-cholesterol O-acyltransferase inhibitors (antiatherosclerotics and anticholesterolemics)

INVENTOR(S): Meguro, Kanju; Tawada, Hiroyuki; Ikeda, Hitoshi


PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 29 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 472116	A1	19920226	EP 1991-113706	19910815
EP 472116	B1	19960131		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05032666	A2	19930209	JP 1991-200393	19910809
JP 3086295	B2	20000911		
US 5143919	A	19920901	US 1991-744492	19910813
CA 2049227	AA	19920218	CA 1991-2049227	19910815
AT 133672	E	19960215	AT 1991-113706	19910815
US 5256782	A	19931026	US 1992-886081	19920520
PRIORITY APPLN. INFO.:			JP 1990-217309	A 19900817
			JP 1991-118444	A 19910523
			US 1991-744492	A3 19910813

OTHER SOURCE(S): MARPAT 116:214482
 GI




AB Certain thienopyridine derivs., e.g., thieno[2,3-b]pyridin-5-yl urea derivs., are claimed. The use of these compds. as acyl CoA-cholesterol O-acyltransferase inhibitors is claimed. Treatment of 5-amino-4-(2-chlorophenyl)-2-ethylthieno[2,3-b]pyridine with 2,4-difluorophenyl isocyanate gave thieno[2,3-b]pyridine urea I. I had activity as an acyl CoA-cholesterol O-acyltransferase inhibitor.

IT **141059-63-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as acyl CoA-cholesterol acyltransferase inhibitor)



RN 141059-63-4 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-b]pyridin-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1991:607869 CAPLUS
 DOCUMENT NUMBER: 115:207869
 TITLE: Preparation of quinoline derivatives as
 anticholesteroleemics
 INVENTOR(S): Meguro, Kanji; Ikeda, Hitoshi
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9109017	A1	19910627	WO 1990-JP1617	19901210
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 03181465	A2	19910807	JP 1989-322172	19891211
CA 2071224	AA	19910612	CA 1990-2071224	19901210
EP 505565	A1	19920930	EP 1991-900058	19901210
EP 505565	B1	19940427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06503550	T2	19940421	JP 1991-500700	19901210
JP 3040159	B2	20000508		
AT 104965	E	19940515	AT 1991-900058	19901210
JP 3040159	B2	20000508	JP 1990-500700	19901210
US 5362742	A	19941108	US 1991-646735	19910201
US 5523407	A	19960604	US 1994-280664	19940727
PRIORITY APPLN. INFO.:				
			JP 1989-322172	A 19891211
			JP 1989-322171	A 19891211
			EP 1991-900058	A 19901210
			WO 1990-JP1617	W 19901210
			US 1991-646735	A3 19910201
OTHER SOURCE(S):				
GI				
MARPAT 115:207869				




AB Title compds. I [R = substituent(s); X = R1C:N (R1 = H, alkyl, alkoxy), R2NCO (R2 = H, alkyl); Y = (CH2)m (m = 0-2), CH:CH; Z = (substituted) Ph, certain (substituted) heterocyclyl; 1 = 0, 1] and salts are prepd. I possess inhibitory action against acyl-CoA-cholesterol acyltransferase (II). 3-Amino-4-(2-chlorophenyl)-6,8-dimethylquinoline, 3,5-di-tert-Bu-4-hydroxybenzoic acid, diethylphosphoryl cyanide, and DMF were added to Et3N in DMF to give the quinoline deriv. III. In II inhibitory activity, 6-chloro-4-(2-chlorophenyl)-3-(3,4-dihydroxycinnamoylamino)quinoline-HBr (also prepd.) at 10-6M showed 97.0% inhibition.


IT 136432-40-1P 136432-41-2P 136432-42-3P
136432-43-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as anticholesteremic)


RN 136432-40-1 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 136432-41-2 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 136432-42-3 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 136432-43-4 CAPLUS
CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-3,5-bis(1,1-dimethylethyl)-4-hydroxy- (9CI) (CA INDEX NAME)



L8 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:187494 CAPLUS
 DOCUMENT NUMBER: 116:187494
 TITLE: Synthesis and 5-HT receptors binding studies of some
 3-substituted-2-(4-methyl-1-piperazinyl)-4-phenylquinolines
 AUTHOR(S): Anzini, Maurizio; Cappelli, Andrea; Vomero, Salvatore;
 Campiani, Giuseppe; Cagnotto, Alfredo; Skorupska,
 Malgorzata
 CORPORATE SOURCE: Dip. Farm. Chim. Tecnol., Univ. Siena, Siena, 53100,
 Italy
 SOURCE: Farmaco (1991), 46(12), 1435-47
 CODEN: FRMCE8
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The syntheses of some 3-substituted-2-(4-methyl-1-piperazinyl)-4-phenylquinolines I (R = alkyl) are reported. The title compounds were tested for their potential activities on 5-HT receptor subtypes and 5-HT uptake site; the compounds showed micromolar affinity for 5-HT₃ and 5-HT uptake site.
 IT **140842-11-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 140842-11-1 CAPLUS
 CN 3-Quinolinemethanol, 2-(4-methyl-1-piperazinyl)-4-phenyl-, benzoate
 (ester) (9CI) (CA INDEX NAME)



L8 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1990:55616 CAPLUS
 DOCUMENT NUMBER: 112:55616
 TITLE: Preparation of 7-(4-aryl-3-pyridyl)-3,5-dihydroxy-6-heptenoates and analogs as hypocholesteremics
 INVENTOR(S): Angerbauer, Rolf; Fey, Peter; Huebsch, Walter; Philipps, Thomas; Bischoff, Hilmar; Petzinna, Dieter; Schmidt, Delf; Thomas, Guenter
 PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
 SOURCE: Eur. Pat. Appl., 132 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 325130	A2	19890726	EP 1989-100250	19890109
EP 325130	A3	19901205		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
DE 3801406	A1	19890727	DE 1988-3801406	19880120
NO 8900047	A	19890721	NO 1989-47	19890105
NO 177005	B	19950327		
NO 177005	C	19950705		
EP 1123924	A1	20010816	EP 2001-109309	19890109
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
EP 1123925	A1	20010816	EP 2001-109310	19890109
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
CN 1034364	A	19890802	CN 1989-100326	19890117
CN 1055684	B	20000823		
DD 283400	A5	19901010	DD 1989-325090	19890117
FI 8900258	A	19890721	FI 1989-258	19890118
FI 93007	B	19941031		
FI 93007	C	19950210		
AU 8928617	A1	19890720	AU 1989-28617	19890119
AU 642127	B2	19931014		
DK 8900233	A	19890721	DK 1989-233	19890119
JP 01216974	A2	19890830	JP 1989-8770	19890119
JP 2558344	B2	19961127		
ZA 8900429	A	19900228	ZA 1989-429	19890119
HU 50776	A2	19900328	HU 1989-214	19890119
HU 210727	B	19950728		
HU 52053	A2	19900628	HU 1989-5141	19890119
CN 1274719	A	20001129	CN 2000-102357	20000217
PRIORITY APPLN. INFO.:			DE 1988-3801406	A 19880120
			IT 1988-21317	A 19880711
			EP 1989-100250	A3 19890109

GI




AB The title compds. [I; A = (un)substituted aryl, heteroaryl; B = cycloalkyl, (un)substituted alkyl; D, E = H, cyano, NO₂, cycloalkyl, (un)substituted alkyl, heteroaryl, aryl, etc.; DE = COZ(CH₂)_m, WZCR13R14(CH₂)_m; R = CH(OH)CH₂CR₂₁(OH)CH₂CO₂R₂₂, Q; R13, R14 = (un)substituted aryl, aralkyl, heteroaryl; R₂₁ = H, alkyl; R₂₂ = H, alkyl, aryl, aralkyl, cation; W = CO, CHOH; X = CH₂CH₂, CH:CH; Z = O, S, CH₂, (un)substituted imino; m = 1-3] were prep'd. Thus, 4-FC6H₄CH:C(COCHMe₂)CO₂Et (prepn. given) was refluxed 18 h with Me₂CHC(NH₂):CHCO₂Et in EtOH and the product stirred 1 h with DDQ (oxidizing agent) in CH₂Cl₂ to give phenylpyridinedicarboxylate II (R₁ = R₂ = CO₂Et) which was converted in 4 steps to II (R₁ = PhCH₂OCH₂, R₂ = CHO). The latter was refluxed in THF with di-Et [2-(cyclohexylamino)vinyl]phosphonate which had been treated with NaH and the product refluxed with (CO₂H)₂ in PhMe to give II [R₂ = (E)-CH:CHCHO] which was condensed with MeCOCH₂CO₂Me which had been treated with 2 equiv. amts. NaH to give, after redn., title compd. II [R₁ = PhCH₂OCH₂, R₂ = erythro-(E)-CH:CHCH(OH)CH₂CH(OH)CH₂CO₂Me] which gave 66% redn. of serum cholesterol in dogs receiving 8 mg/kg orally daily.

IT 124863-88-3P 124863-89-4P 124863-90-7P
124863-91-8P 124863-92-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of hypocholesteremics)


RN 124863-88-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 124863-89-4 CAPLUS

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 124863-90-7 CAPLUS
 CN 3-Pyridinecarboxaldehyde, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 124863-91-8 CAPLUS
 CN 2-Propenal, 3-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 124863-92-9 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-5-hydroxy-3-oxo-, methyl ester, (E)-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 124863-93-0P 124864-31-9P 124864-38-6P
 124864-78-4P 124864-80-8P 124865-18-5P
 124865-22-1P 124865-23-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as hypocholesteremic)

RN 124863-93-0 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester,
 [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 124864-31-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester,
 [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 124864-38-6 CAPLUS


CN 6-Heptenoic acid, 7-[5-[(benzoyloxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-
 methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-78-4 CAPLUS
CN 6-Heptenoic acid, 7-[2,4-bis(4-fluorophenyl)-6-methyl-5-
[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester,
[R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-80-8 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-1-oxido-
5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester,
[R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124865-18-5 CAPLUS
 CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]ethenyl]tetrahydro-4-hydroxy-,
 [4.alpha.,6.beta.(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 124865-22-1 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 124865-23-2 CAPLUS
 CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy]methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]ethenyl]tetrahydro-4-hydroxy-, [4.alpha.,6.beta.(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



L8 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1988:186578 CAPLUS
 DOCUMENT NUMBER: 108:186578
 TITLE: Preparation of tetrahydropyridine-3-carboxylic acids, esters, and amides as therapeutic agents for amnesia and senile dementia
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62192358	A2	19870822	JP 1987-32590	19870217
JP 08032682	B4	19960329		
US 4745123	A	19880517	US 1986-830035	19860218
CA 1285939	A1	19910709	CA 1987-528411	19870128
EP 235663	A1	19870909	EP 1987-102216	19870217
EP 235663	B1	19900725		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 54910	E	19900815	AT 1987-102216	19870217
ES 2029801	T3	19921001	ES 1987-102216	19870217
PRIORITY APPLN. INFO.:			US 1986-830035	19860218
			EP 1987-102216	19870217

OTHER SOURCE(S): CASREACT 108:186578
 GI




AB The title compds. [I; R1 = H, C1-6 alkyl, C1-6 alkenyl, C2-5 alkoxy carbonyl, C4-8 cycloalkyl, (halo, OH, C1-6 alkyl, or C1-4 alkyloxy substituted) PhC1-6alkyl; when R2 = H, R4R6 = bond or when R6 = H, R2R4 = bond; R3 = CO2R7, CONR8R9; R5 = C1-6 alkyl, C1-6 alkenyl, C3-8 cycloalkyl, 2- or 3-thienyl, Ph, halo, NO2, amino, etc.; R7 = C1-6 alkyl, C1-6 alkenyl, C3-8 cycloalkyl, Ph etc.; R8, R9 = H, C1-4 alkyl, or when R8 = H, R9 = C3-8 cycloalkyl, PhCH2O, (substituted) Ph alkyl, or R8R9N = pyrrolidinyl, piperidinyl, morpholino, etc.], useful for treatment of senile dementia and as cholinergic agents, are prepd. from II (R3, R5 = same as I), via III (R1, R3, R5 = same as I; X = halo). II (R3 = CO2H; R5 = Ph) in CH2Cl2 was treated with SO2Cl2 in the presence of Et3N, followed by addn. of Me2NH to give II (R3 = CONMe2; R5 = Ph) which was treated with EtI to afford III (R1 = Et; R3 = CONMe2; R5 = Ph; X = iodo) and redn. of the latter compd. with NaBH4 in EtOH in the presence of 1M HCl gave I (R1 = Et; R2R4 = bond; R3 = CONMe2; R5 = Ph; R6 = H) (IV). IV was converted to its oxalate which showed IC50 of 9 .mu.M at muscarinic receptors, vs. 1.1 .mu.M for arecoline.

IT **114120-64-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conversion of, to pyridinium salt)

RN 114120-64-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT **114120-68-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of, tetrahydropyridine analog from)

RN 114120-68-2 CAPLUS

CN Pyridinium, 4-phenyl-3-[[(phenylmethyl) amino] carbonyl]-1-propyl-, iodide
(9CI) (CA INDEX NAME)

● I⁻

L8 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1972:85718 CAPLUS
 DOCUMENT NUMBER: 76:85718
 TITLE: 4-Phenyl-3-(acylamino)quinolines
 INVENTOR(S): Meguro, Kanji; Kuwada, Yutaka; Henmi, Teruji; Yamano, Togo
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2116507	A	19711202	DE 1971-2116507	19710405
NO 133758	B	19760315	NO 1971-1173	19710329
NL 7104487	A	19711006	NL 1971-4487	19710402
FR 2092001	A5	19720121	FR 1971-11652	19710402
FR 2092001	B1	19750606		
AT 304555	B	19730110	AT 1971-2831	19710402
HU 163639	P	19730927	HU 1971-TA1113	19710402
SE 360867	B	19731008	SE 1971-4360	19710402
SU 402213	D	19731012	SU 1971-1641012	19710402
DK 127927	B	19740204	DK 1971-1585	19710402
US 3798226	A	19740319	US 1971-130853	19710402
CH 559185	A	19750228	CH 1971-4793	19710402
CS 161127	P	19750504	CS 1971-2384	19710402
ES 389890	A1	19730601	ES 1971-389890	19710403
BE 765287	A1	19710830	BE 1971-101802	19710405
FI 49604	B	19750430	FI 1971-947	19710405
GB 1290818	A	19720927	GB 1971-1290818	19710419
			JP 1970-28850	19700404

PRIORITY APPLN. INFO.:


GI For diagram(s), see printed CA Issue.

AB The title compds. (I), effective against Trichomonas and abscesses, were
 prepd. by acylation of corresponding 3-aminoquinolines. Thus, 3.8 parts I
 (R = H, R1 = Cl), prepd. from (2-amino-5-chloro-.alpha.-
 phenylbenzylideneamino)acetaldehyde di-Et acetal, reacted with 10 parts
 Ac2O to give 4.2 parts I (R = Ac, R1 = Cl). Similarly prepd. were 19
 addnl. I, e.g. (R and R1 given): Ac, Br; Ac, MeO; p-ClC6H4CH2CO, Cl.
 3-Acetamido-6,7-dimethoxy-4-phenylquinoline and 2 3-
 (diacetylamino)quinolines were also prepd.


IT **35404-26-3P 35519-44-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 35404-26-3 CAPLUS
 CN Benzeneacetamide, 4-chloro-N-(6-chloro-4-phenyl-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 35519-44-9 CAPLUS
 CN Benzeneacetamide, N-(6-chloro-4-phenyl-3-quinolinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 33 OF 52 USPATFULL

ACCESSION NUMBER: 2001:179276 USPATFULL

TITLE: Process for the preparation of pyridine derivatives
 INVENTOR(S): Hilpert; Hans, Reinach, Switzerland
 Hoffmann-Emery, Fabienne, Birsfelden, Switzerland
 Rimmner, Goesta, Bad Krozingen, Germany, Federal Republic of

Rogers-Evans, Mark, Ettingen, Switzerland
 Stahr, Helmut Werner, Lorrach, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Waldmeier, Pius, Wegenstetten, Switzerland
 Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303790	B1	20011016
APPLICATION INFO.:	US 2000-716538		20001120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-123686	19991129
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davis, Zinna Northington	
LEGAL REPRESENTATIVE:	Johnston, George W., Rocha-Tramaloni, Patricia S., Ebel, Eileen M.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	924	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is described for preparing certain 4-alkyl- or 4-aryl-pyridine derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 342417-03-2P

(process for prepn. of pyridine derivs.)

RN 342417-03-2 USPATFULL


CN 3-Pyridinecarboxamide, 6-chloro-4-(2-methylphenyl)-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)

IT 290296-68-3P 290297-57-3P 342416-86-8P

(process for prepn. of pyridine derivs.)


RN 290296-68-3 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 342416-86-8 USPATFULL

CN 3-Pyridinecarboxamide, 4-(2-methylphenyl)-6-(4-morpholinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 34 OF 52 USPATFULL
 ACCESSION NUMBER: 2001:168255 USPATFULL
 TITLE: 4-phenyl-pyridine derivatives
 INVENTOR(S): Bos, Michael, Montreal, Canada
 Branca, Quirico, Binningen, Switzerland
 Galley, Guido, Rheinfelden, Germany, Federal Republic
 of
 Godel, Thierry, Basel, Switzerland
 Hoffmann, Torsten, Birsfelden, Switzerland
 Hunkeler, Walter, Magden, Switzerland
 Schnider, Patrick, Oberwil, Switzerland
 Stadler, Heinz, Rheinfelden, Switzerland
 PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6297375	B1	20011002
APPLICATION INFO.:	US 2000-507456		20000222 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-103504	19990224
	EP 1999-123689	19991129
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
LEGAL REPRESENTATIVE:	Johnston, George W., Epstein, William H., Dawson, Arthur D.	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3340	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of the related invention are related to 4-phenyl-pyridine derivatives connected by a bridge containing oxygen or nitrogen to a phenyl derivative.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 290297-14-2P 290297-18-6P 290297-26-6P
 290297-30-2P

(prepn. of N-benzyl-4-tolylnicotinamides and related compds. as neurokinin-1 receptor antagonists)


RN 290297-14-2 USPATFULL

CN Benzeneacetamide, N-[6-amino-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 290297-18-6 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-26-6 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290297-30-2 USPATFULL

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 290296-41-2P 290296-42-3P 290296-43-4P
 290296-44-5P 290296-45-6P 290296-46-7P
 290296-47-8P 290296-48-9P 290296-49-0P
 290296-50-3P 290296-51-4P 290296-52-5P
 290296-53-6P 290296-54-7P 290296-55-8P
 290296-56-9P 290296-57-0P 290296-58-1P
 290296-59-2P 290296-60-5P 290296-61-6P
 290296-62-7P 290296-63-8P 290296-65-0P
 290296-66-1P 290296-67-2P 290296-68-3P
 290296-69-4P 290296-70-7P 290296-71-8P
 290296-72-9P 290296-73-0P 290296-74-1P
 290296-75-2P 290296-76-3P 290296-77-4P

290296-78-5P 290296-79-6P 290296-80-9P
 290296-81-0P 290296-82-1P 290296-83-2P
 290296-84-3P 290296-85-4P 290296-86-5P
 290296-87-6P 290296-88-7P 290296-89-8P
 290296-90-1P 290296-91-2P 290296-92-3P
 290296-93-4P 290296-94-5P 290296-95-6P
 290296-96-7P 290296-98-9P 290296-99-0P
 290297-00-6P 290297-01-7P 290297-02-8P
 290297-03-9P 290297-04-0P 290297-05-1P
 290297-06-2P 290297-07-3P 290297-08-4P
 290297-09-5P 290297-10-8P 290297-11-9P
 290297-12-0P 290297-13-1P 290297-15-3P
 290297-16-4P 290297-17-5P 290297-57-3P
 290297-59-5P 290297-60-8P 290297-61-9P
 290297-62-0P 290297-63-1P 290297-64-2P
 290297-65-3P 290297-66-4P 290298-21-4P

(prepn. of N-benzyl-4-tolylnicotinamides and related compds. as
 neurokinin-1 receptor antagonists)


RN 290296-41-2 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-
 4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-42-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-
 chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-43-4 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-
 4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 290296-44-5 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 290296-45-6 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-46-7 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 290296-47-8 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-ethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-48-9 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 290296-49-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-50-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[(3,5-difluorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-51-4 USPATFULL

CN 3-Pyridinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-52-5 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-53-6 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-54-7 USPATFULL


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-55-8 USPATFULL


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 290296-56-9 USPATFULL

CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 290296-57-0 USPATFULL
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-
 trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX
 NAME)



● HCl


RN 290296-58-1 USPATFULL
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-
 pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX
 NAME)



HCl


RN 290296-59-2 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-60-5 USPATFULL


CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290296-61-6 USPATFULL

CN Benzeneacetamide, N,.alpha.-dimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 290296-62-7 USPATFULL


CN Cyclopropanecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-3-pyridinyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

NAME)




● HCl

RN 290296-63-8 USPATFULL
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, hydrochloride (2:3)
 (9CI) (CA INDEX NAME)



● 3/2 HCl


RN 290296-65-0 USPATFULL
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride
 (9CI) (CA INDEX NAME)



HCl


RN 290296-66-1 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-67-2 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-68-3 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-69-4 USPATFULL

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 290296-70-7 USPATFULL
 CN Benzeneacetamide, N-[6-(dimethylamino)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 290296-71-8 USPATFULL
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)



RN 290296-72-9 USPATFULL
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1-
 piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 290296-73-0 USPATFULL

CN Benzeneacetamide, N-[6-(4-hydroxy-1-piperidiny)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)

RN 290296-74-1 USPATFULL


CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 290296-75-2 USPATFULL

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-76-3 USPATFULL

CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290296-77-4 USPATFULL

CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-78-5 USPATFULL

CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




3 HCl

RN 290296-79-6 USPATFULL


CN 3-Pyridinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-

4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-80-9 USPATFULL

CN Pyridine, 3-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-81-0 USPATFULL



CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-82-1 USPATFULL


CN 3-Pyridinemethanamine, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 290296-83-2 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 290296-84-3 USPATFULL

CN 1-Piperazineacetic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290296-85-4 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290296-86-5 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-87-6 USPATFULL

CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-88-7 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[methyl(2-(4-morpholinyl)ethyl)amino]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-89-8 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-90-1 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-91-2 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-92-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-93-4 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-94-5 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-95-6 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(cyanomethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-96-7 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-98-9 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1,2,4-oxadiazol-3-ylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 290296-99-0 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290297-00-6 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-01-7 USPATFULL
 CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-02-8 USPATFULL

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(1-methylnaphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-03-9 USPATFULL


CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-04-0 USPATFULL
 CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290297-05-1 USPATFULL
 CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-06-2 USPATFULL
 CN 3-Pyridinecarboxamide, N-[(2-chloro-5-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-07-3 USPATFULL

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 290297-08-4 USPATFULL

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-09-5 USPATFULL

CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-10-8 USPATFULL


CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-11-9 USPATFULL
 CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 290297-12-0 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1H-tetrazol-5-ylmethyl)-1-piperazinyl]]- (9CI) (CA INDEX NAME)




RN 290297-13-1 USPATFULL
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(phenylmethyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-15-3 USPATFULL

CN Benzeneacetamide, N-[6-[[[(dimethylamino)methylene]amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-16-4 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(methylsulfonyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-17-5 USPATFULL

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(phenylsulfonyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 USPATFULL


CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290297-59-5 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 290297-60-8 USPATFULL
 CN 4-Piperidineacetic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290297-61-9 USPATFULL
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-62-0 USPATFULL

CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-63-1 USPATFULL

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-64-2 USPATFULL

CN Benzeneacetamide, N,.alpha.-dimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-65-3 USPATFULL


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290297-66-4 USPATFULL
 CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290298-21-4 USPATFULL
 CN Benzeneacetamide, N-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 290297-47-1
 (prepn. of N-benzyl-4-tolynicotinamides and related compds. as neurokinin-1 receptor antagonists)

RN 290297-47-1 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 290297-31-3P 290297-41-5P

(prepn. of N-benzyl-4-tolynicotinamides and related compds. as neurokinin-1 receptor antagonists)


RN 290297-31-3 USPATFULL

CN Cyclopropanecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-3-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 290297-41-5 USPATFULL

CN Carbamic acid, [5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 35 OF 52 USPATFULL

ACCESSION NUMBER:

2000:153704 USPATFULL

TITLE:

INVENTOR(S):

Cyclic compounds, their production and use
 Natsugari, Hideaki, Hyogo, Japan
 Ishimaru, Takenori, Osaka, Japan
 Doi, Takayuki, Osaka, Japan
 Ikeura, Yoshinori, Nara, Japan
 Kimura, Chiharu, Hyogo, Japan
 Takeda Chemical Industries, Ltd., Osaka, Japan
 (non-U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER

KIND

DATE

Searched by Barb O'Bryen STIC 308-4291

PATENT INFORMATION: US 6147071 20001114
APPLICATION INFO.: US 1998-87894 19980601 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1996-621360, filed on 25 Mar
1996, now patented, Pat. No. US 5786352

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-91436	19950324
	JP 1995-207553	19950720
	JP 1995-264727	19950918
	JP 1996-30033	19960123
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4990	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds of the following general formula or salts thereof.
##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.CC<, --CO--N< or --CS--N< as the partial structure --X Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Ring C is optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183550-95-0P 183551-05-5P 183551-08-8P

183551-09-9P 183551-11-3P 183551-12-4P

183551-16-8P 183551-20-4P 183551-21-5P

183551-25-9P 183551-26-0P 183551-27-1P

183551-28-2P 183551-29-3P 183551-30-6P

183551-31-7P 183551-32-8P 183551-33-9P

183551-34-0P 183551-35-1P 183551-36-2P

183551-37-3P 183551-47-5P 183551-48-6P

183551-49-7P 183551-50-0P 183551-56-6P



183551-58-8P 183551-59-9P 183551-61-3P

183551-67-9P 183551-68-0P

(prepn. of polycyclic heterocycles as tachykinin receptor antagonists)


RN 183550-95-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-05-5 USPATFULL

CN 3-Pyridinecarboxamide, N-(2-aminoethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-08-8 USPATFULL

CN Carbamic acid, [2-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(2-chloro-4-phenyl-3-pyridinyl)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 183551-09-9 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-11-3 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 183551-12-4 USPATFULL
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
 N-(3-hydroxypropyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-16-8 USPATFULL
 CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-
 (2-hydroxyethyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-20-4 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-21-5 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-25-9 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-26-0 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[2-(2-hydroxyethyl)(phenylmethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-27-1 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(3-hydroxypropyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-28-2 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (3-hydroxypropyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-29-3 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 183551-30-6 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dichlorophenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-31-7 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-32-8 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-33-9 USPATFULL


CN 3-Pyridinecarboxamide, 2-chloro-N-(3-hydroxypropyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 183551-34-0 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-35-1 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-36-2 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 183551-37-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-47-5 USPATFULL
CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 183551-48-6 USPATFULL
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183551-49-7 USPATFULL
CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-50-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-56-6 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-58-8 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



NAME)

Absolute stereochemistry.




RN 183551-59-9 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-61-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-67-9 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl-N3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-68-0 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl)methyl]-N2-ethyl-N3-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 36 OF 52 USPATFULL

ACCESSION NUMBER: 2000:67737 USPATFULL

TITLE: Cycloalkano-pyridines

INVENTOR(S): Schmidt, Gunter, Wuppertal, Germany, Federal Republic of
 Brandes, Arndt, Wuppertal, Germany, Federal Republic of
 Angerbauer, Rolf, Kobe, Japan
 Logers, Michael, Wuppertal, Germany, Federal Republic of
 Muller-Gliemann, Matthias, Solingen, Germany, Federal Republic of
 Schmeck, Carsten, Wuppertal, Germany, Federal Republic of
 Bremm, Klaus-Dieter, Recklinghausen, Germany, Federal Republic of
 Bischoff, Hilmar, Wuppertal, Germany, Federal Republic of
 Schmidt, Delf, Wuppertal, Germany, Federal Republic of
 Schuhmacher, Joachim, Wuppertal, Germany, Federal Republic of
 Giera, Henry, Bergisch Gladbach, Germany, Federal Republic of
 Paulsen, Holger, Wuppertal, Germany, Federal Republic of

PATENT ASSIGNEE(S):

Naab, Paul, Wuppertal, Germany, Federal Republic of
 Conrad, Michael, Wuppertal, Germany, Federal Republic
 of
 Stoltefuss, Jurgen, Haan, Germany, Federal Republic of
 Bayer Aktiengesellschaft, Leverkusen, Germany, Federal
 Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6069148		20000530
APPLICATION INFO.:	US 1997-889530		19970708 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19627419	19960708
	DE 1997-19707199	19970224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Norris, McLaughlin & Marcus, P.A.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2897	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The, cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hyperlipoproteinaemia and arteriosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



IT 202203-35-8P 202203-36-9P 202203-37-0P

202203-44-9P 202203-45-0P 202203-46-1P

(prepn. of tetrahydroquinolines and analogs as cholesteryl ester
 transfer protein inhibitors)



RN 202203-35-8 USPATFULL

CN 5-Quinolinol, 2,4-bis(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-36-9 USPATFULL

CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-37-0 USPATFULL

CN 5-Quinolinol, 2-cyclopentyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-3-[[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 202203-44-9 USPATFULL


CN 5-Quinolinol, 4-(4-fluorophenyl)-3-[[[4-(fluorophenyl)methoxy]methyl]-5,6,7,8-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 202203-45-0 USPATFULL
 CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
 [[[3-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 202203-46-1 USPATFULL
 CN 5-Quinolinol, 4-(4-fluorophenyl)-5,6,7,8-tetrahydro-2-(1-methylethyl)-3-
 [[[4-(trifluoromethyl)phenyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 37 OF 52 USPATFULL
 ACCESSION NUMBER: 1999:132843 USPATFULL
 TITLE: 4-aryl-3-aminoquinoline-2-one derivatives as potassium
 channel modulators
 INVENTOR(S): Hewawasam, Piyasena, Middletown, CT, United States
 Starrett, Jr., John E., Middletown, CT, United States
 Swartz, Stephen G., Warrington, PA, United States
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972961		19991026
APPLICATION INFO.:	US 1998-138638		19980824 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-58014	19970828 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Mach, D M	
LEGAL REPRESENTATIVE:	Algieri, Aldo A.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1799	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel 4-aryl-3-aminoquinolin-2-one derivatives having the general formula ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein, or a non-toxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium-activated K.sup.+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221112-59-0P 221112-61-4P 221112-71-6P
221112-72-7P

(prep. of 4-aryl-3-aminoquinoline-2-ones as potassium channel modulators)


RN 221112-59-0 USPTFULL

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 221112-61-4 USPTFULL

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 221112-71-6 USPTFULL

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 221112-72-7 USPATFULL

CN Benzeneacetamide, N-[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]-4-hydroxy- (9CI) (CA INDEX NAME)



L8 ANSWER 38 OF 52 USPATFULL

ACCESSION NUMBER: 1998:88837 USPATFULL

TITLE: Cyclic compounds, their production and use

INVENTOR(S): Natsugari, Hideaki, Hyogo, Japan

Ishimaru, Takenori, Osaka, Japan

Doi, Takayuki, Osaka, Japan

Ikeura, Yoshinori, Nara, Japan

Kimura, Chiharu, Hyogo, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5786352		19980728
APPLICATION INFO.:	US 1996-621360		19960325 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-91436	19950324
	JP 1995-207553	19950720
	JP 1995-264727	19950918
	JP 1996-30033	19960123

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Kifle, Bruck
 LEGAL REPRESENTATIVE: Foley & Lardner
 NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 LINE COUNT: 4948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds of the following general formula or salts thereof.
 ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<,
 --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and
 R.sup.b are bonded to each other to form Ring A, or they are the same or
 different and represent, independently, a hydrogen atom or a substituent
 on the Ring M; Ring A and Ring B represent, independently, an optionally
 substituted homocyclic or heterocyclic ring, and at least one of them is
 optionally substituted heterocyclic ring; Ring C is optionally
 substituted homocyclic or heterocyclic ring; Ring Z is an optionally
 substituted ring; and n represents an integer of from 1 to 6, or a salt
 thereof, which has an excellent tachykinin receptor antagonistic effect,
 and their production, and pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183550-95-0P 183551-05-5P 183551-08-8P

183551-09-9P 183551-11-3P 183551-12-4P

183551-16-8P 183551-20-4P 183551-21-5P

183551-25-9P 183551-26-0P 183551-27-1P

183551-28-2P 183551-29-3P 183551-30-6P

183551-31-7P 183551-32-8P 183551-33-9P

183551-34-0P 183551-35-1P 183551-36-2P

183551-37-3P 183551-47-5P 183551-48-6P

183551-49-7P 183551-50-0P 183551-56-6P



183551-58-8P 183551-59-9P 183551-61-3P

183551-67-9P 183551-68-0P

(prepn. of polycyclic heterocycles as tachykinin receptor antagonists)


RN 183550-95-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-05-5 USPATFULL

CN 3-Pyridinecarboxamide, N-(2-aminoethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-08-8 USPATFULL

CN Carbamic acid, [2-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(2-chloro-4-phenyl-3-pyridinyl)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 183551-09-9 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-11-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-12-4 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(3-hydroxypropyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-16-8 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-20-4 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-21-5 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(2-hydroxyethyl)-N2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-25-9 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-hydroxyethyl)amino]carbonyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-26-0 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[2-hydroxyethyl](phenylmethyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 183551-27-1 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(3-hydroxypropyl)-N2,5-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-28-2 USPATFULL

CN 2-Pyridinecarboxylic acid, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N3-(3-hydroxypropyl)amino]carbonyl]-5-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 183551-29-3 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 183551-30-6 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dichlorophenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-31-7 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-(2-hydroxyethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-32-8 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-33-9 USPATFULL


CN 3-Pyridinecarboxamide, 2-chloro-N-(3-hydroxypropyl)-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 183551-34-0 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-35-1 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-36-2 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-37-3 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183551-47-5 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-48-6 USPATFULL


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-(2-hydroxyethyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 183551-49-7 USPATFULL

CN 3-Pyridinecarboxamide, 2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-50-0 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-56-6 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2S)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183551-58-8 USPATFULL



CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
N-[(2R)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 183551-59-9 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
N-(2-hydroxyethyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 183551-61-3 USPATFULL

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-
N-(3-hydroxypropyl)-6-methyl-4-phenyl- (9CI) (CA INDEX NAME)





RN 183551-67-9 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-(2-hydroxyethyl)-N2,5-dimethyl-4-phenyl-N3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 183551-68-0 USPATFULL

CN 2,3-Pyridinedicarboxamide, N3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N2-ethyl-N3-(2-hydroxyethyl)-5-methyl-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 39 OF 52 USPATFULL

ACCESSION NUMBER: 97:120627 USPATFULL

TITLE: Condensed heterocyclic compounds, their production and use

INVENTOR(S): Natsugari, Hideaki, Ashiya, Japan
Ikeda, Hitoshi, Higashiosaka, Japan
Ishimaru, Takenori, Toyonaka, Japan
Doi, Takayuki, Izumi, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5700810		19971223
APPLICATION INFO.:	US 1995-540913		19951011 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-114841, filed on 2 Sep 1993, now patented, Pat. No. US 5482967		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-237481	19920904
	JP 1993-103328	19930428

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Mach, D. Margaret M.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 7893

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compound represented by the formula: ##STR1## wherein A", B, C, D, E, G, Ar, X, Y, and Z are defined herein or a salt thereof. The compounds have excellent activity of inhibiting ACAT, lowering Cholesterol in blood and inhibiting tachykinin receptor, or a salt thereof, their production and use.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 159818-59-4P 159818-65-2P 159818-66-3P
159818-67-4P 159818-68-5P 159818-69-6P
159818-70-9P 159818-71-0P 159818-72-1P
159818-73-2P

(prepn. and biol. activity of)


RN 159818-59-4 USPTAFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-65-2 USPTAFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-66-3 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-67-4 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-68-5 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-69-6 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,6,7-trimethoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-70-9 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-71-0 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-72-1 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylamino)-4-phenyl- (9CI) (CA INDEX NAME)



RN 159818-73-2 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylthio)-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 40 OF 52 USPATFULL

ACCESSION NUMBER: 97:112487 USPATFULL

TITLE: Heterocyclic-substituted alkyl amide ACAT inhibitors

INVENTOR(S): Lee, Helen Tsenwei, Ann Arbor, MI, United States

O'Brien, Patrick Michael, Stockbridge, MI, United States

Picard, Joseph Armand, Ypsilanti, MI, United States

Purchase, Jr., Claude Forsey, Ann Arbor, MI, United States

Roth, Bruce David, Ann Arbor, MI, United States

Sliskovic, Drago Robert, Ypsilanti, MI, United States

White, Andrew David, Lakeland, MI, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693657		19971202
APPLICATION INFO.:	US 1997-786062		19970121 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-433776, filed on 3 May 1995 which is a division of Ser. No. US 1994-274088, filed on 12 Jul 1994, now patented, Pat. No. US 5441975, issued on 15 Aug 1995 which is a division of Ser. No. US 1993-19411, filed on 18 Feb 1993, now patented, Pat. No. US 5366987, issued on 22 Nov 1994 which is a continuation of Ser. No. US 1992-913643, filed on 20 Jul 1992, now abandoned which is a continuation of Ser. No. US 1991-748568, filed on 22 Aug 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gupta, Yogendra N.		
LEGAL REPRESENTATIVE:	Crissey, Todd M.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3299		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Pharmaceutically useful compounds having ACAT inhibitory activity of the formula ##STR1## wherein n is 0, 1, or 2, for X other than tetrazole and n=2 then R.sub.2 .dbd.R.sub.3 .dbd.H; R.sub.1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, a heteroaromatic group or a hydrocarbon group having from one to 18 carbon atoms; R.sub.2 and R.sub.3 are hydrogen, halo, hydroxy, alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl, a heteroaryl, or form a spiroalkyl group; X is a heteromonocyclic 5-membered ring containing one to four heteroatoms, said heteroatoms being nitrogen, oxygen or sulfur, and combination thereof; and R.sub.4 is a hydrocarbon group having from one to 20 carbon atoms are described as well as methods of their manufacture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148926-65-2P

(prepn. of, as cholesterol acyltransferase inhibitor)

RN 148926-65-2 USPATFULL

CN 2H-Tetrazole-5-acetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-
2-dodecyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)

L8 ANSWER 41 OF 52 USPATFULL

ACCESSION NUMBER: 97:59228 USPATFULL

TITLE: Tetrazole alkyl amide acat inhibitors

INVENTOR(S): Lee, Helen Tsenwhei, Ann Arbor, MI, United States
O'Brien, Patrick Michael, Stockbridge, MI, United StatesPicard, Joseph Armand, Ypsilanti, MI, United States
Purchase, Jr., Claude Forsey, Ann Arbor, MI, United StatesRoth, Bruce David, Ann Arbor, MI, United States
Sliskovic, Drago Robert, Ypsilanti, MI, United States

White, Andrew David, Lakeland, MI, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646170		19970708
APPLICATION INFO.:	US 1995-433776		19950503 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-274088, filed on 12 Jul 1994, now patented, Pat. No. US 5441975 which is a division of Ser. No. US 1993-19411, filed on 18 Feb 1993, now patented, Pat. No. US 5366987 which is a continuation-in-part of Ser. No. US 1992-913643, filed on 20 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-748568, filed on 22 Aug 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gupta, Yogendra N.		
LEGAL REPRESENTATIVE:	Crissey, Todd M.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3394		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutically useful compounds having ACAT inhibitory activity of the formula ##STR1## wherein n is 0, 1, or 2, for X other than tetrazole and n=2 then R.sub.2 .dbd.R.sub.3 .dbd.H; R.sub.1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, a heteroaromatic group or a hydrocarbon group having from one to 18 carbon atoms; R.sub.2 and R.sub.3 are hydrogen, halo, hydroxy, alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl, a heteroaryl, or form a spiroalkyl group; X is a heteromonocyclic 5-membered ring containing one to four heteroatoms, said heteroatoms being nitrogen, oxygen or sulfur, and combination

thereof; and R.sub.4 is a hydrocarbon group having from one to 20 carbon atoms are described as well as methods of their manufacture.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148926-65-2P

(prepn. of, as cholesterol acyltransferase inhibitor)

RN 148926-65-2 USPATFULL

CN 2H-Tetrazole-5-acetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2-dodecyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 42 OF 52 USPATFULL

ACCESSION NUMBER: 96:116392 USPATFULL

TITLE: Heterocyclic compounds, their production and use as tachykinin receptor antagonists

INVENTOR(S): Natsugari, Hideaki, Hyogo, Japan
Ishimaru, Takenori, Osaka, Japan
Doi, Takayuki, Osaka, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5585385		19961217
APPLICATION INFO.:	US 1994-338762		19941110 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-281178	19931110
	JP 1993-337488	19931228
	JP 1994-33637	19940303
	JP 1994-138551	19940621

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Huang, Evelyn
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 4054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel compound represented by the formula: ##STR1## wherein Ring A and Ring B respectively stands for an optionally substituted homo- or hetero-cyclic ring, and at least one of them stands for an optionally substituted heterocyclic ring stand; Ring C stands for an optionally substituted benzene ring; R stands for a hydrogen atom or an optionally substituted hydrocarbon residue; one of X and Y stands for --NR^{sup.1}-- (R^{sup.1} stands for a hydrogen atom or an optionally substituted hydrocarbon residue) or --O--, and the other stands for --CO-- or --CS--, or one of them stands for --N.dbd. and the other stands for

.dbd.CR.sup.2 -- (R.sup.2 stands for a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon residue, an optionally substituted amino group or an optionally substituted hydroxyl group); n denotes 1 or 2 or salts thereof which have an excellent tachykinin receptor antagonistic action and inhibitory action on plasma extravasation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 168541-24-0P

(prepn. of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compds. as tachykinin antagonists and inhibitors of plasma extravasation)

RN 168541-24-0 USPATFULL

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 43 OF 52 USPATFULL

ACCESSION NUMBER: 96:3760 USPATFULL

TITLE: Condensed heterocyclic compounds, their production and use

INVENTOR(S): Natsugari, Hideaki, Ashiya, Japan
Ikeda, Hitoshi, Higashiosaka, Japan
Ishimaru, Takenori, Toyonaka, Japan
Doi, Takayuki, Izumi, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5482967		19960109
APPLICATION INFO.:	US 1993-114841		19930902 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-237481	19920904
	JP 1993-103328	19930428

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Mach, D. Margaret M.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 7705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compound represented by the formula: ##STR1## such as 6-Chloro-N-(2,6-diethoxyphenyl)-4-(2-methylphenyl-2-oxo-2H-1-benzopyran-3-acetamide: ##STR2## or a salt thereof. The compound has an excellent activity of inhibiting ACAT, lowering the cholesterol in blood and

inhibiting tachykinin receptor. The present invention also relates to the production and use of the disclosed compound.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 159818-59-4P 159818-65-2P 159818-66-3P
159818-67-4P 159818-68-5P 159818-69-6P
159818-70-9P 159818-71-0P 159818-72-1P
159818-73-2P

(prepn. and biol. activity of) .


RN 159818-59-4 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-65-2 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-66-3 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-67-4 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-68-5 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-69-6 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,6,7-trimethoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-70-9 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-71-0 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 159818-72-1 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methoxycarbonyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 159818-73-2 USPATFULL

CN 3-Quinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylthio)-4-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 44 OF 52 USPATFULL

ACCESSION NUMBER: 95:73656 USPATFULL

TITLE: Pyrazolo-substituted alkyl amide acat inhibitors

INVENTOR(S): Lee, Helen T., Ann Arbor, MI, United States

O'Brien, Patrick M., Stockbridge, MI, United States

Picard, Joseph A., Ypsilanti, MI, United States

Purchase, Jr., Claude F., Ann Arbor, MI, United States

Roth, Bruce D., Ann Arbor, MI, United States

Sliskovic, Drago R., Ypsilanti, MI, United States

White, Andrew D., Lakeland, MI, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5441975		19950815
APPLICATION INFO.:	US 1994-274088		19940712 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-19411, filed on 18 Feb 1993, now patented, Pat. No. US 5366987 which is a continuation-in-part of Ser. No. US 1992-913643, filed on 20 Jul 1992, now abandoned which is a		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Gupta, Yogendra N.
 LEGAL REPRESENTATIVE: Ashbrook, Charles W.
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 LINE COUNT: 3280

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutically useful compounds having ACAT inhibitory activity of the formula ##STR1## wherein n is 0, 1, or 2, for X other than tetrazole and n=2 then R.sub.2 =R.sub.3 =H; R.sub.1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, a heteroaromatic group or a hydrocarbon group having from one to 18 carbon atoms; R.sub.2 and R.sub.3 are hydrogen, halo, hydroxy, alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl, a heteroaryl, or form a spiroalkyl group; X is a heteromonocyclic 5-membered ring containing one to four heteroatoms, said heteroatoms being nitrogen, oxygen or sulfur, and combination thereof; and R.sub.4 is a hydrocarbon group having from one to 20 carbon atoms are described as well as methods of their manufacture.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148926-65-2P

(prepn. of, as cholesterol acyltransferase inhibitor)

RN 148926-65-2 USPATFULL

CN 2H-Tetrazole-5-acetamide, N-[4-(2-chlorophenyl)-6,8-dimethyl-3-quinolinyl]-2-dodecyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 45 OF 52 USPATFULL

ACCESSION NUMBER: 95:45608 USPATFULL

TITLE: Tricyclic heterocyclic compounds, their production and use

INVENTOR(S): Meguro, Kanji, Nishinomiya, Japan
 Tawada, Hiroyuki, Takatsuki, Japan
 Ikeda, Hitoshi, Higashiosaka, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5418239		19950523
APPLICATION INFO.:	US 1993-117950		19930908 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-765182, filed on 25 Sep 1991, now patented, Pat. No. US 5264454		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-259657	19900927

DOCUMENT TYPE: JP 1991-202003 19910812
 Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Rotman, Alan L.
 LEGAL REPRESENTATIVE: Foley & Lardner
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1487

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel heterocyclic compound of the general formula: ##STR1## wherein ring A and ring B each means a benzene ring which is substituted or unsubstituted; X means a group of the formula: ##STR2## wherein R.sup.2 is hydrogen an alkyl or an alkoxy; m is 0 or 1, the formula: ##STR3## wherein R.sup.3 is hydrogen or an alkyl, or the formula: --O--CO--; Y means a bond, --NH--, an C.sub.1 or 2 alkylene group or --CH.dbd.CH--; R.sup.1 means a hydrocarbon group which is substituted or unsubstituted; and n means a whole number of 3 through 6, or a salt thereof, having excellent acyl-CoA:cholesterol acyltransferase inhibitory activity, and a method for preparing it and its use.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 142626-36-6P

(prepn. of, as cholesterol acyltransferase inhibitor)

RN 142626-36-6 USPATFULL

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-7,8-dihydro-6H-cyclopenta[g]quinolin-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



L8 ANSWER 46 OF 52 USPATFULL

ACCESSION NUMBER: 95:36385 USPATFULL

TITLE: Substituted pyridines

INVENTOR(S): Angerbauer, Rolf, Wuppertal, Germany, Federal Republic of
 Fey, Peter, Wuppertal, Germany, Federal Republic of
 Hubsch, Walter, Wuppertal, Germany, Federal Republic of
 Philipps, Thomas, Cologne, Germany, Federal Republic of
 Bischoff, Hilmar, Wuppertal, Germany, Federal Republic of
 Krause, Hans-Peter, Schwelm, Germany, Federal Republic of
 von Gehr, Jorg P., Bochum, Germany, Federal Republic of
 Schmidt, Delf, Wuppertal, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5409910		19950425
APPLICATION INFO.:	US 1993-169804		19931217 (8)

NUMBER DATE

 PRIORITY INFORMATION: DE 1992-42440297 19921224
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Ivy, C. Warren
 ASSISTANT EXAMINER: Owens, A. A.
 LEGAL REPRESENTATIVE: Sprung Horn Kramer & Woods
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 LINE COUNT: 577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New substituted pyridines are prepared by reducing suitably substituted pyridine derivatives. The new substituted pyridines are suitable as active compounds in pharmaceuticals, in particular for the treatment of hyperlipoproteinaemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 157199-23-0P


(prepn. of, as HMG CoA reductase inhibitor anticholesteremic)

RN 157199-23-0 USPATFULL

CN 6-Heptene-1,3,5-triol, 7-[4-(4-fluorophenyl)-5-[[4-(fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-, [S-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 157199-27-4


(reactant for [(fluorophenyl)pyridinyl]heptenetriol anticholesteremic)

RN 157199-27-4 USPATFULL

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-[[4-(fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, [S-[R*,S*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● Na

L8 ANSWER 47 OF 52 USPATFULL

ACCESSION NUMBER: 95:27313 USPATFULL

TITLE: Substituted pyridines heptenoic acid derivatives,
useful for treating arteriosclerosis, lipopotaemia and
the likeINVENTOR(S): Angerbauer, Rolf, Wuppertal, Germany, Federal Republic
of
Fey, Peter, Wuppertal, Germany, Federal Republic of
Hubsch, Walter, Wuppertal, Germany, Federal Republic of
Philipps, Thomas, Cologne, Germany, Federal Republic of
Bischoff, Hilmar, Wuppertal, Germany, Federal Republic
of
Petzinna, Dieter, Duesseldorf, Germany, Federal
Republic of
Schmidt, Delf, Wuppertal, Germany, Federal Republic of
Thomas, Gunter, Arese, ItalyPATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal
Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5401746		19950328
APPLICATION INFO.:	US 1992-916928		19920720 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-627086, filed on 13 Dec 1990, now patented, Pat. No. US 5169857 which is a continuation-in-part of Ser. No. US 1989-298549, filed on 17 Jan 1989, now patented, Pat. No. US 5006530		

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1980-2131788	19800711
	DE 1988-33014068	19880120
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3725	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds for treating hyperproteinaemia, lipoproteinaemia or
arteriosclerosis of the formula ##STR1## in which A, B, D and E can have

varied meanings,

X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--, and

R is ##STR2## wherein R.sup.21 --denotes hydrogen or alkyl and

R.sup.22 --denotes hydrogen,

denotes alkyl, aryl or aralkyl, or

denotes a cation,

and their oxidation products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 124863-88-3P 124863-89-4P 124863-90-7P

124863-91-8P 124863-92-9P

(prepn. and reaction of, in prepn. of hypocholesteremics)


RN 124863-88-3 USPATFULL

CN 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 124863-89-4 USPATFULL

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 124863-90-7 USPATFULL


CN 3-Pyridinecarboxaldehyde, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 124863-91-8 USPATFULL

CN 2-Propenal, 3-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 124863-92-9 USPATFULL

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]-5-hydroxy-3-oxo-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 124863-93-0P 124864-31-9P 124864-38-6P
124864-78-4P 124864-80-8P 124865-18-5P
124865-22-1P 124865-23-2P

(prepn. of, as hypocholesteremic)

RN 124863-93-0 USPATFULL


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*, S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-31-9 USPATFULL
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-38-6 USPATFULL
CN 6-Heptenoic acid, 7-[5-[(benzoyloxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-78-4 USPATFULL
CN 6-Heptenoic acid, 7-[2,4-bis(4-fluorophenyl)-6-methyl-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124864-80-8 USPATFULL
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-1-oxido-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 124865-18-5 USPATFULL
CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-pyridinyl]ethenyl]tetrahydro-4-hydroxy-, [4.alpha.,6.beta.(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 124865-22-1 USPATFULL

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 124865-23-2 USPATFULL

CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]ethenyl]tetrahydro-4-hydroxy-, [4.alpha.,6.beta.(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L8 ANSWER 48 OF 52 USPATFULL

ACCESSION NUMBER: 93:98398 USPATFULL

TITLE: Certain 2-oxo-tetrahydro-cycloalkyl-benzopyran-3yl
ureas having acyl-CoA-cholesterol acyl transferase
inhibitory activity

INVENTOR(S): Meguro, Kanji, Nishinomiya, Japan
 Tawada, Hiroyuki, Takatsuki, Japan
 Ikeda, Hitoshi, Higashiosaka, Japan
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5264454		19931123
APPLICATION INFO.:	US 1991-765182		19910925 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-259657	19900927
	JP 1991-202003	19910812
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1,8	
LINE COUNT:	1443	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel heterocyclic compound of the general formula: ##STR1## wherein ring A and ring B each means a benzene ring which is substituted or unsubstituted; X means a group of the formula: ##STR2## wherein R.sup.2 is hydrogen, an alkyl or an alkoxy; m is 0 or 1, the formula: ##STR3## wherein R.sup.3 is hydrogen or an alkyl, or the formula: --O--CO--; Y means a bond, --NH--, an C.sub.1 or 2 alkylene group or --CH.dbd.CH--; R.sup.1 means a hydrocarbon group which is substituted or unsubstituted; and n means a whole number of 3 through 6, or a salt thereof, having excellent acyl-CoA:cholesterol acyltransferase inhibitory activity, and a method for preparing it and its use.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 142626-36-6P

(prepn. of, as cholesterol acyltransferase inhibitor)

RN 142626-36-6 USPATFULL

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-7,8-dihydro-6H-cyclopenta[g]quinolin-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



L8 ANSWER 49 OF 52 USPATFULL

ACCESSION NUMBER: 93:89788 USPATFULL

TITLE: Thienopyridine derivatives which are intermediates

INVENTOR(S): Meguro, Kanji, Nishinomiya, Japan

Tawada, Hiroyuki, Takatsuki, Japan

Ikeda, Hitoshi, Higashiosaka, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5256782		19931026
APPLICATION INFO.:	US 1992-886081		19920520 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-744492, filed on 13 Aug 1991, now patented, Pat. No. US 5143919		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-217309	19900817
	JP 1991-118444	19910523
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dentz, Bernard	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1111	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Thienopyridine derivatives of the formula (I): ##STR1## wherein the ring A is an optionally substituted benzene ring; the ring B is an optionally substituted thiophene ring; X is a group of the formula: ##STR2## (wherein R.sup.1 is hydrogen, alkyl or alkoxy; and n is 0 or 1) or a group of the formula: ##STR3## (wherein R.sup.2 is hydrogen or alkyl); Y is a single bond, --NH--, alkylene having 1 or 2 carbon atoms or --CH.dbd.CH--; and R.sup.3 is an optionally substituted hydrocarbon group, or their salts are disclosed. They show strong ACAT inhibitory activities.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 141059-63-4P

(prepn. of, as acyl CoA-cholesterol acyltransferase inhibitor)

RN 141059-63-4 USPATFULL

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-b]pyridin-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



L8 ANSWER 50 OF 52 USPATFULL

ACCESSION NUMBER: 92:72473 USPATFULL

TITLE: Thienopyridine derivatives and their pharmaceutical use

INVENTOR(S): Meguro, Kanji, Nishinomiya, Japan

Tawada, Hiroyuki, Takatsuki, Japan

Ikeda, Hitoshi, Higashiosaka, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5143919		19920901
APPLICATION INFO.:	US 1991-744492		19910813 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-217309	19900817
	JP 1991-118444	19910523
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dentz, Bernard	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1136	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Thienopyridine derivatives of the formula (I): ##STR1## wherein the ring A is an optionally substituted benzene ring; the ring B is an optionally substituted thiophene ring; X is a group of the formula: ##STR2## (wherein R.sup.1 is hydrogen, alkyl or alkoxy; and n is 0 or 1) or a group of the formula: ##STR3## (wherein R.sup.2 is hydrogen or alkyl); Y is a single bond, --NH--, alkylene having 1 or 2 carbon atoms or --CH.dbd.CH--; and R.sup.3 is an optionally substituted hydrocarbon group, or their salts are disclosed. They show strong ACAT inhibitory activities.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 141059-63-4P

(prepn. of, as acyl CoA-cholesterol acyltransferase inhibitor)

RN 141059-63-4 USPATFULL

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-b]pyridin-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



L8 ANSWER 51 OF 52 USPATFULL

ACCESSION NUMBER: 91:28596 USPATFULL

TITLE: Certain 7-[2,6-diisopropyl-4-phenyl-5-lower alkoxyethyl-pyrid-3-yl]-3,5-dihydroxy-6-enoates and derivatives useful for treating circulatory diseases

INVENTOR(S): Angerbauer, Rolf, Wuppertal, Germany, Federal Republic of
 Fey, Peter, Wuppertal, Germany, Federal Republic of
 Hubsch, Walter, Wuppertal, Germany, Federal Republic of
 Philipps, Thomas, Cologne, Germany, Federal Republic of
 Bischoff, Hilmar, Wuppertal, Germany, Federal Republic of
 Petzinna, Dieter, Duesseldorf, Germany, Federal Republic of
 Schmidt, Delf, Wuppertal, Germany, Federal Republic of
 Thomas, Gunter, Arese, Italy
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 5006530 19910409
 APPLICATION INFO.: US 1989-298549 19890117 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1988-3801406	19880120
	IT 1988-21317	19880711
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1,18	
LINE COUNT:	3639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula ##STR1## in which A, B, D and E can have varied meanings,

X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--, and

R is ##STR2## wherein R.sup.21 denotes hydrogen or alkyl and

R.sup.22

denotes hydrogen,

denotes alkyl, aryl or aralkyl, or

denotes a cation,

and their oxidation products.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 124863-88-3P 124863-89-4P 124863-90-7P
 124863-91-8P 124863-92-9P

(prepn. and reaction of, in prepn. of hypocholesteremics)


RN 124863-88-3 USPATFULL

CN 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 124863-89-4 USPATFULL

CN 3-Pyridinemethanol, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 124863-90-7 USPATFULL

CN 3-Pyridinecarboxaldehyde, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)

RN 124863-91-8 USPATFULL

CN 2-Propenal, 3-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]-3-pyridinyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 124863-92-9 USPATFULL

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
[(phenylmethoxy)methyl]-3-pyridinyl]-5-hydroxy-3-oxo-, methyl ester,
(E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 124863-93-0P 124864-31-9P 124864-38-6P
 124864-78-4P 124864-80-8P 124865-18-5P
 124865-22-1P 124865-23-2P

(prepn. of, as hypocholesteremic)

RN 124863-93-0 USPATFULL

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester,
 [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 124864-31-9 USPATFULL

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester,
 [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 124864-38-6 USPATFULL

CN 6-Heptenoic acid, 7-[5-[(benzoyloxy)methyl]-4-(4-fluorophenyl)-2,6-bis(1-
 methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 124864-78-4 USPATFULL

CN 6-Heptenoic acid, 7-[2,4-bis(4-fluorophenyl)-6-methyl-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 124864-80-8 USPATFULL


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-methyl-2-(1-methylethyl)-1-oxido-5-[(phenylmethoxy)methyl]-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 124865-18-5 USPATFULL
 CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-
 [(phenylmethoxy)methyl]-3-pyridinyl]ethenyl]tetrahydro-4-hydroxy-,
 [4.alpha.,6.beta.(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 124865-22-1 USPATFULL
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, methyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 124865-23-2 USPATFULL
 CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5-[[4-(4-fluorophenyl)methoxy)methyl]-2,6-bis(1-methylethyl)-3-pyridinyl]ethenyl]tetrahydro-4-hydroxy-, [4.alpha.;6.beta.(E)]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



L8 ANSWER 52 OF 52 USPATFULL
 ACCESSION NUMBER: 88:31069 USPATFULL
 TITLE: Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
 INVENTOR(S): Butler, Donald E., Holland, MI, United States
 Dodd, John H., Lebanon, NJ, United States
 Moos, Walter H., Ann Arbor, MI, United States
 Tecle, Haile, Ann Arbor, MI, United States
 PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4745123		19880517
APPLICATION INFO.:	US 1986-830035		19860218 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brust, Joseph Paul		
LEGAL REPRESENTATIVE:	Janssen, Jerry F.		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1,20,21		
LINE COUNT:	1362		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain substituted 1,2,3,6-tetrahydro- and 1,2,5,6-tetrahydropyridine-3-carboxylic acids, esters, and amides possessing muscarinic binding activity, having utility for the treatment of the symptoms of senile cognitive decline disclosed. Pharmaceutical compositions and a pharmaceutical method of treatment are also disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 114120-64-8P

(prepn. and conversion of, to pyridinium salt)

RN 114120-64-8 USPATFULL


CN 3-Pyridinecarboxamide, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 114120-68-2P

(prepn. and redn. of, tetrahydropyridine analog from)

RN 114120-68-2 USPATFULL

CN Pyridinium, 4-phenyl-3-[[phenylmethyl]amino]carbonyl]-1-propyl-, iodide
(9CI) (CA INDEX NAME)● I⁻

FILE 'CAOLD' ENTERED AT 14:07:47 ON 04 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```

L1          STR
L4          401 SEA FILE=REGISTRY SSS=FUL L1
L7          0 SEA FILE=CAOLD ABB=ON L4

```

FILE 'HOME' ENTERED AT 14:07:47 ON 04 JAN 2002

=> d saved

NAME	CREATED	NOTES/TITLE
EIN209SEQ1/A	TEMP	91 ANSWERS IN FILE REGISTRY
EIN209SEQ2/A	TEMP	12 ANSWERS IN FILE REGISTRY
MAU792FULL/A	TEMP	37 ANSWERS IN FILE REGISTRY
MIT185CAAU/A	TEMP	1 ANSWER IN FILE CAPLUS
MIT842CAAU/A	TEMP	2 ANSWERS IN FILE CAPLUS
OZG803CA1/A	TEMP	0 ANSWERS IN FILE CAPLUS
OZG803CA2/A	TEMP	1 ANSWER IN FILE CAPLUS
OZG803CA3/A	TEMP	7 ANSWERS IN FILE CAPLUS
OZG803CA4/A	TEMP	0 ANSWERS IN FILE CAPLUS
OZG803CA5/A	TEMP	2 ANSWERS IN FILE CAPLUS
OZG803CA6/A	TEMP	15 ANSWERS IN FILE CAPLUS
PAT066FULL/A	TEMP	401 ANSWERS IN FILE REGISTRY
PAT417FULL/A	TEMP	104 ANSWERS IN FILE REGISTRY
SLOB696SEQ/A	TEMP	20 ANSWERS IN FILE REGISTRY

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.15	402.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-19.82

SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 14:08:33 ON 04 JAN 2002